

# *CURRICULUM VITAE*

---

## LIST OF CONTENTS

<b>1. PERSONAL DETAILS</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>3</b>
<b>2. BRIEF BIOGRAPHY</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>4</b>
<b>3. QUALIFICATIONS</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>5</b>
<b>4. EDUCATION</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>6</b>
<b>5. ADVANCED COURSES</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>6</b>
<b>6. AWARDS-PRIZES-SCHOLARSHIPS</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>7</b>
<b>7. PRESENT POSITION</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>7</b>
<b>8. PROFESSIONAL EXPERIENCE (IN BRIEF)</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>8</b>
<b>9. PUBLICATIONS</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>9</b>
<b>A. Referred Journal Manuscripts</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>9</b>
<b>B. Books</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>19</b>
<b>C. Electronic Journals</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>22</b>
<b>10. PUBLICATIONS IN CONFERENCE PROCEEDINGS</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>23</b>
<b>A. International Conferences</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>23</b>
<b>B. National Conferences</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>37</b>
<b>11. INVITED LECTURES</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>40</b>
<b>A. International Conferences</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>40</b>
<b>B. National Conferences</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>43</b>
<b>12. RESEARCH FUNDING</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>50</b>
<b>13. TEACHING</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>51</b>
<b>A. Undergraduate Education</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>51</b>
<b>B. Postgraduate Education</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>51</b>
<b>C. Supervision of MSc Students, PhD Students and Postdoctoral Scientists</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>52</b>
<b>14. ESPE ACTIVITIES AND AWARDS</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>52</b>
<b>15. ORGANIZATION OF CONFERENCES</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>52</b>
<b>16. MEMBERSHIP IN EDITORIAL BOARDS AND SOCIETY BOARDS</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>53</b>
<b>17. MEMBERSHIP IN COMMITTEES AND SOCIETIES</b>	.....	.....	.....	.....	.....	.....	.....	.....	<b>53</b>

## 1. PERSONAL DETAILS

---

***EVANGELIA CHARMANDARI, MD, MSc, PhD, MRCP(UK), CCST(UK)***

**Name:** Evangelia Charmandari

**Nationality:** Hellenic



**Home address:** 21 Aimilias Dafni Street, Neo Psychiko  
Athens, 11525, Greece

**Present position:** Professor of Pediatrics – Pediatric and Adolescent Endocrinology

**Work address:** Division of Endocrinology, Metabolism and Diabetes  
First Department of Pediatrics  
National and Kapodistrian University of Athens Medical School  
'Aghia Sophia' Children's Hospital  
Thivon and Papdiamantopoulou Street  
Athens, 11527, Greece

**Work Telephone numbers:** +30-213-2013-239 and +30-6947-904369

**E-mail address:** [evangelia.charmandari@googlemail.com](mailto:evangelia.charmandari@googlemail.com)

## 2. BRIEF BIOGRAPHY

---

Evangelia Charmandari graduated from the Aristotle University Medical School, Thessaloniki, Greece, as a valedictorian of her class, and completed her specialization in General Pediatrics in the United Kingdom (UK). She was further subspecialized in Pediatric and Adolescent Endocrinology at the London Centre for Paediatric Endocrinology and Metabolism, Great Ormond Street Hospital for Children, The Middlesex Hospital and University College Hospital in London, UK. She is a certified General Pediatrician and Pediatric and Adolescent Endocrinologist by the Royal College of Pediatrics and Child Health, London, UK. She was also awarded a MSc in Clinical Pediatrics and a PhD in Pediatric and Adolescent Endocrinology by the University College London (UCL), University of London, London, UK, in 1998 and 2001, respectively. She subsequently undertook a Postdoctoral Fellowship in Molecular Endocrinology and Cellular Biology at the National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, Maryland, USA (2000-2004). She worked as a Consultant in Pediatric and Adolescent Endocrinology at St. James' University Hospital and Leeds General Infirmary, Leeds, UK (2006-2007). Following 15 years of clinical and research work in the UK and USA, she returned back to Greece in 2007 having been awarded a European Union Reintegration Grant. She used this opportunity to establish and develop the Laboratory of Molecular Endocrinology and Cellular Biology at the Division of Endocrinology and Metabolism, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece (2007-2011).

Dr. Charmandari was elected an Associate Professor of Pediatric and Adolescent Endocrinology at the National and Kapodistrian University of Athens Medical School in July 2009 and a Full Professor of Pediatrics – Pediatric and Adolescent Endocrinology in July 2015. She carries out her clinical, research, teaching and administrative commitments at the Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, 'Aghia Sophia' Hospital for Children, Athens, Greece. She also supervises the Laboratory of Hormonal Measurements and Molecular Endocrinology at Choremeio Research Institution, 'Aghia Sophia' Children's Hospital, while she remains the main scientific supervisor of the Laboratory of Molecular Endocrinology and Cellular Biology at the Division of Endocrinology and Metabolism, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

She has been actively involved in the teaching of Medical Students, Senior House Officers (Residents) in General Pediatrics, Fellows in Endocrinology, Undergraduate and Postgraduate Students, as well as Postdoctoral Scientists. She has been the main scientific supervisor of 2 Undergraduate Students, 10 MSc Students, 3 PhD Students and 3 Postdoctoral Scientists, who have completed their research projects, while she continues to supervise 8 MSc Students, 5 PhD Students and 1 Postdoctoral Scientist, whose research studies are still ongoing. She has been the main organizer of the European Postgraduate Program 'New Inroads to Child Health (NICHe) Conference' and 'ESPE Science School' of the European Society for Pediatric Endocrinology in 2012, which was entitled 'Stress Response and Child Health' (Heraklio, Crete, 2012), and has successfully organized several seminars in General Pediatrics and Pediatric Endocrinology.

Professor Charmandari's research work has focused primarily on the hypothalamic-pituitary-adrenal axis and its disorders, growth disorders and childhood obesity. Her research work includes research projects in Clinical research, Translational research and Basic research in Molecular Endocrinology and Cellular Biology. Her clinical research has focused on Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Primary Hyperaldosteronism, Cushing syndrome and Childhood Obesity. Her basic research studies have focused on Primary Generalized Glucocorticoid Resistance and Hypersensitivity, and the molecular mechanisms of glucocorticoid action.

She has 333 publications (106 articles in SCI journals, 8 in non-SCI journal, 1 book, 55 chapters in books, and 130 in international conference proceedings, and 33 in national conference proceedings), which have a total impact factor of 560,377 and received 6427 citations (h-index=40, i10-index: 76). She was awarded the ‘Henning Andersen Prize’ of the European Society of Pediatric Endocrinology (basic research), as well as several prizes of the Hellenic Endocrine Society, Hellenic Society of Adolescent Medicine and Health Business Awards. She has been an invited speaker in more than 130 National and International Meetings.

Finally, she has been actively involved in attracting research funding. As a main Principal Investigator (PI), she has attracted funding of 1,688,000.00 Euros, while as co-PI, she has attracted an additional 789,000.00 Euros (Total amount of funding: 2,477,000.00). During the last 7 years, she has been the Scientific Supervisor and Coordinator of the Program entitled ‘Development of a National System of the Prevention and Management of Obesity in Childhood and Adolescence’, and Artificial Intelligence Algorithms for Personalized Management of Obesity in Childhood and Adolescence, which are funded by the European Union and the General Secretariat of Research and Development, Greece.

### 3. QUALIFICATIONS

---

1. **Certificate of Completion of Sub-Specialty Training in Pediatric Endocrinology**  
Awarded by: Royal College of Pediatrics and Child Health, London, UK  
Date awarded: September 5, 2005
2. **Certificate of Completion of Specialty Training in General Pediatrics**  
Awarded by: Royal College of Pediatrics and Child Health, London, UK  
Date awarded: September 5, 2005
3. **Degree of Doctor of Medicine (PhD Equivalent)**  
Awarded by: University College London, University of London, London UK  
Date awarded: July 31, 2001
4. **Master of Science in Clinical Pediatrics**  
Awarded by: University College London, University of London, London UK  
Date awarded: November 1, 1998
5. **Certificate of Completion of Specialist Training in Pediatrics**  
Awarded by: Aristotelian University Medical School, Thessaloniki, Greece  
Date awarded: November 21, 1998
6. **Membership of Royal College of Physicians [MRCP (UK)], Part II**  
Awarded by: Royal College of Physicians, London, UK  
Date awarded: June 25, 1996
7. **Membership of Royal College of Physicians [MRCP (UK)], Part I**  
Awarded by: Royal College of Physicians, London, UK  
Date awarded: July 12, 1994
8. **Medical Degree (with Highest Distinction)**  
Awarded by: Aristotle University Medical School, Thessaloniki, Greece  
Date awarded: November 2, 1988

#### 4. EDUCATION

---

- 1982 - 1988:           **Medical Student**, Aristotle University Medical School, Thessaloniki, Greece
- 1997 – 2000:           **PhD Fellow**, University College London, University of London, UK
- 2000 – 2004:           **Postdoctoral Fellow**, Pediatric and Reproductive Endocrinology Branch,  
National Institute of Child Health and Human Development (NICHD),  
National Institutes of Health (NIH), Bethesda, Maryland, USA

#### 5. ADVANCED COURSES

---

1.     **European Society for Pediatric Endocrinology (ESPE) Summer School**  
Brussels, Belgium, September 1997 (5 days)
2.     **Recombinant DNA Methodology, FAES Bio-Trac 2**  
National Institutes of Health, Bethesda, Maryland, USA, Winter Session 2001 (3 months)
3.     **Expression, Detection and Purification of Recombinant Proteins in Prokaryotic and Eukaryotic Cells, FAES Bio-Trac 16**  
National Institutes of Health, Bethesda, Maryland, USA, Fall Session 2003 (3 months)
4.     **Genome Analysis, FAES Bio-Trac 11**  
National Institutes of Health, Bethesda, Maryland, USA, Winter Session 2004 (3 months)
5.     **Advanced Postgraduate Course on Growth and Growth Disorders**  
Stockholm, Sweden, June 2005 (5 days)
6.     **5th National PUMP Conference – Insulin Pump Therapy in Practice**  
London, United Kingdom, October 2006 (1 day)
7.     **Advanced Course in Pediatric Bone and Calcium Metabolism**  
Birmingham, United Kingdom, March 2007 (2 days)
8.     **Medtronic Course on Insulin Pump Therapy**  
London, United Kingdom, April 2007 (1 day)
9.     **Advance life support courses – Cardiopulmonary resuscitation**  
London, United Kingdom, once yearly
10.    **Management Course for Consultants**  
Imperial College, London, United Kingdom, 2006

## **6. AWARDS – PRIZES – SCHOLARSHIPS**

---

1. **National Scholarship – IKY**, 1982, 1983, 1984, 1985, 1986, 1987, 1988
2. **Henning Andersen Prize**, European Society for Pediatric Endocrinology, June 2007
3. **Prize for Best Research Proposal in Pediatric Endocrinology**, Hellenic Endocrine Society, 2010
4. **Prize for Best Research Proposal in Pediatric Endocrinology**, Hellenic Endocrine Society, 2012
5. **‘Farmakioti’ Prize for best Poster Presentation**, Hellenic Endocrine Society, 2013
6. **Prize for Best Basic Science Research in Endocrinology**, Hellenic Endocrine Society, 2016
7. **‘Ikkou’ Prize for Best Clinical Research in Endocrinology**, Hellenic Endocrine Society, 2016
8. **e-Health Award – Electronic applications for a comprehensive care of patients**, Health Care Business Awards, 2016
9. **Prize for Best Basic Science Research in Endocrinology**, Hellenic Endocrine Society, 2017
10. **‘Georgios Maragkos’ Prize**, Hellenic Society for Adolescent Medicine, 2019
11. **‘Sotiris Papastamatis’ Prize**, Athens Medical Society, 2019

## **7. PRESENT POSITION**

---

**DIVISION OF ENDOCRINOLOGY, METABOLISM AND DIABETES  
FIRST DEPARTMENT OF PEDIATRICS  
UNIVERSITY OF ATHENS MEDICAL SCHOOL  
‘AGHIA SOPHIA’ CHILDREN’S HOSPITAL**

**Position:** Professor of Pediatric and Adolescent Endocrinology  
**Duration:** December 11, 2015 – Present  
&  
**Position:** Associate Professor of Pediatric and Adolescent Endocrinology  
**Duration:** February 2, 2011 – December 10, 2015

During this time, I have been working initially as an Associate Professor and subsequently as a Full Professor of Pediatric and Adolescent Endocrinology at the Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, National and Kapodistrian University of Athens Medical School, ‘Aghia Sophia’ Children’s Hospital, Athens, Greece, with clinical, research, teaching and administrative commitments. My duties include supervision and management of children and adolescents with endocrine problems at the Out-patient Endocrinology Clinics, as well as patients with endocrine problems admitted to other Departments of the Hospital. In addition, I have been responsible for the Laboratory of Hormonal Measurements and Molecular Endocrinology at Choremeio Research Institution, ‘Aghia Sophia’ Children’s Hospital, as well as the Laboratory of Molecular Endocrinology and Cellular Biology at the Division of Endocrinology and Metabolism, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

I have been actively involved in the teaching of Medical Students, Senior House Officers (Residents) in General Pediatrics, Fellows in Endocrinology, Undergraduate and Postgraduate students, as well as Postdoctoral Scientists. I have been the main scientific supervisor of 2 Undergraduate Students, 10 MSc Students, 3 PhD Students and 3 Postdoctoral Scientists, who have completed their research projects, while I continue to supervise 8 MSc Students, 5 PhD Students and 1 Postdoctoral Scientist, whose research studies are still ongoing. I have also been the main

organizer of the European Postgraduate Program ‘New Inroads to Child Health (NICHe) Conference’ and ‘ESPE Science School’ of the European Society for Pediatric Endocrinology in 2012, which was entitled ‘Stress Response and Child Health’ (Heraklio, Crete, 2012), and I have successfully organized several seminars in General Pediatrics and Pediatric Endocrinology.

My research work has focused primarily on the hypothalamic-pituitary-adrenal axis and its disorders, and childhood obesity. Completed or ongoing research projects include projects relating to Clinical research, Translational research and Basic research in Molecular Endocrinology and Cellular Biology. My clinical research projects have focused on Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Primary Hyperaldosteronism, Cushing syndrome and Childhood Obesity. My basic research projects have focused on Primary Generalized Glucocorticoid Resistance and Hypersensitivity, and the molecular mechanisms of glucocorticoid action.

Finally, during this time I have been actively involved in attracting research funding. As a main Principal Investigator (PI), I have attracted 1,610,000.00 (one million six hundred ten thousand) Euros, while as co-PI, I have attracted 779,000.00 (seven hundred and seventy nine thousand) Euros. During the last 7 years, I have been the Scientific Supervisor and Coordinator of the Program entitled ‘Development of a National System of the Prevention and Management of Obesity in Childhood and Adolescence’, and Artificial Intelligence Algorithms for Personalized Management of Obesity in Childhood and Adolescence, which are funded by the European Union and the General Secretariat of Research and Development, Greece.

## **8. PROFESSIONAL EXPERIENCE**

---

<b>11/12/2015 – Present:</b>	<b>Professor of Pediatrics - Pediatric and Adolescent Endocrinology</b> National and Kapodistrian University of Athens Medical School ‘Aghia Sophia’ Children’s Hospital, Athens, Greece
<b>2/2/2011 – 10/12/2015:</b>	<b>Associate Professor of Pediatric and Adolescent Endocrinology</b> National and Kapodistrian University of Athens Medical School ‘Aghia Sophia’ Children’s Hospital, Athens, Greece
<b>1/5/2009 – 1/2/2011:</b>	<b>Senior Investigator – Assistant Professor Level</b> Division of Endocrinology and Metabolism Biomedical Research Foundation of the Academy of Athens
<b>1/7/2007 – 31/4/2009:</b>	<b>Senior Investigator in Molecular Endocrinology/Cellular Biology</b> Division of Endocrinology and Metabolism Biomedical Research Foundation of the Academy of Athens
<b>24/7/2006 – 16/4/2007:</b>	<b>Consultant in Pediatric and Adolescent Endocrinology</b> St. James’s University Hospital /Leeds General Infirmary, Leeds, UK
<b>4/9/2004 – 4/3/2006:</b>	<b>Specialist Registrar in Pediatric and Adolescent Endocrinology</b> Great Ormond Street Hospital for Children & University College Hospital, University College London, London, UK
<b>1/12/2000 – 3/9/2004:</b>	<b>Postdoctoral Fellow in Molecular Endocrinology and Cellular Biology</b> National Institute of Child Health and Human Development



National Institutes of Health, Bethesda, Maryland, USA

- 1/9/1998 – 30/11/2000:**     **Research Registrar in Pediatric and Adolescent Endocrinology**  
Great Ormond Street Hospital for Children and University College  
Hospital, University College London, London, UK
- 1/9/1997 – 31/8/1998:**     **Specialist Registrar in Pediatric and Adolescent Endocrinology**  
Great Ormond Street Hospital for Children and University College  
Hospital, University College London, London, UK
- 1/9/1995 – 31/8/1997:**     **Specialist Registrar in General Pediatrics**  
Basildon Hospital, Basildon, and Queen Elizabeth Hospital for  
Children, London, UK
- 1/8/1992 – 31/8/1995:**     **Senior House Officer (Resident) in General Pediatrics**  
Rotation through hospitals in North England, UK (Pontefract and  
Preston General Hospitals, Hope and Withington Hospitals in  
Manchester, Alder Hey Children's Hospital in Liverpool)
- 1/7/1990 – 31/7/1992:**     **Senior House Officer in General Pediatrics**  
Infectious Diseases Hospital, Thessaloniki, Greece

## 9. PUBLICATIONS

---

### A. Refereed Journal Manuscripts

#### Publications in SCI Journals

1. Charmandari E, Brook CGD. 20 years of experience in idiopathic central diabetes insipidus. *Lancet* 1999; 353 (9171): 2212-2213.
2. Koziell A, Charmandari E, Hindmarsh PC, Scambler P, Brook CGD. Frasier syndrome and the Wilm's tumour suppressor Gene. *Clinical Endocrinology (Oxford)* 2000; 52(4): 519-524.
3. Charmandari E, Meadows N, Patel M, Johnston A, Benjamin N. Plasma nitrate concentrations in patients with infective and non-infective enteritis. *Journal of Pediatric Gastroenterology and Nutrition* 2001; 32(4): 423-427.
4. Charmandari E. Is hydrocortisone clearance 50% slower in the evening than in the morning? *Journal of Clinical Endocrinology & Metabolism* 2001; 86(2): 948-949.
5. Charmandari E, Johnston A, Brook CGD, Hindmarsh PC. Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia. *Journal of Endocrinology* 2001; 169(1): 65-70.
6. Charmandari E, Hindmarsh PC, Johnston A, Brook CGD. Alterations in cortisol pharmacokinetics at puberty. *Journal of Clinical Endocrinology & Metabolism* 2001; 86(6): 2701-2708.

7. Charmandari E, Lichtarowicz-Krynska E, Hindmarsh PC, Aynsley-Green A, Brook CGD. Congenital adrenal hyperplasia: management during critical illness. *Archives of Disease in Childhood* 2001; 85(1): 26-28.
8. Charmandari E, Pincus SM, Matthews DR, Dennison E, Fall CHD, Hindmarsh PC. Joint growth hormone and cortisol spontaneous secretion is more asynchronous in older females than their male counterparts. *Journal of Clinical Endocrinology & Metabolism* 2001; 86(7): 3393-3399.
9. Charmandari E, Matthews DR, Johnston A, Brook CGD, Hindmarsh PC. Serum cortisol and 17-hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: Is current replacement therapy satisfactory? *Journal of Clinical Endocrinology & Metabolism* 2001; 86(10): 4679-4685.
10. Charmandari E, Dattani MT, Perry LA, Hindmarsh PC, Brook CGD. Kinetics and effect of percutaneous administration of dihydrotestosterone in children. *Hormone Research* 2001; 56(5-6): 177-181.
11. Charmandari E, Brook CGD, Hindmarsh PC. Why is management of patients with classical congenital adrenal hyperplasia more difficult at puberty? *Archives of Disease in Childhood* 2002; 86(4): 266-269.
12. Charmandari E, Weise M, Bornstein SR, Eisenhofer G, Keil MF, Chrousos GP, Merke DP. Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: Potential clinical implications. *Journal of Clinical Endocrinology & Metabolism* 2002; 87(5): 2114-2120.
13. Charmandari E, Pincus SM, Matthews DR, Johnston A, Brook CGD, Hindmarsh PC. Oral hydrocortisone administration in children with classic 21-hydroxylase deficiency leads to more synchronous joint GH and cortisol Secretion. *Journal of Clinical Endocrinology & Metabolism* 2002; 87(5): 2238-2244.
14. Charmandari E, Johnston A, Honour JW, Brook CGD, Hindmarsh PC. Treatment with flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia. *Journal of Pediatric Endocrinology & Metabolism* 2002; 15(4): 435-439.
15. Charmandari E, Eisenhofer G, Mehlinger SL, Carlson A, Wesley R, Keil MF, Chrousos GP, New MI, Merke DP. Adrenomedullary function may predict phenotype and genotype in classic 21-hydroxylase deficiency. *Journal of Clinical Endocrinology & Metabolism* 2002; 87(7): 3031-3037.
16. Charmandari E, Calis KA, Keil MF, Mohassel MR, Remaley A, Merke DP. Flutamide decreases cortisol clearance in patients with congenital adrenal hyperplasia. *Journal of Clinical Endocrinology & Metabolism* 2002; 87(7): 3197-3200.
17. Kino T, Vottero A, Charmandari E, Chrousos GP. Familial/sporadic glucocorticoid resistance syndrome and hypertension. *Annals of the New York Academy of Sciences* 2002; 970: 101-111.
18. Spoudeas HA, Charmandari E, Brook CGD. Hypothalamo-pituitary-adrenal axis integrity after radiotherapy for childhood posterior fossa tumours. *Medical and Pediatric Oncology* 2003; 40(4): 224-229.

19. Charmandari E, Kino T, Souvatzoglou E, Chrousos GP. Pediatric stress: Hormonal mediators and stress response. *Hormone Research* 2003; 59(4): 161-179.
20. Roche E, Charmandari E, Dattani MT, Hindmarsh PC. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency) – A preliminary report. *Clinical Endocrinology (Oxford)* 2003; 58(5): 589-596.
21. Kino T, DeMartino M, Charmandari E, Mirani M, Chrousos GP. Tissue glucocorticoid resistance/hypersensitivity syndromes. *Journal of Steroid Biochemistry and Molecular Biology* 2003; 85(2-5): 457-467.
22. Charmandari E, Pincus SM, Matthews DR, Johnston A, Brook CGD, Hindmarsh PC. Sexual dimorphism in the synchrony of joint growth hormone and cortisol secretion in children with classic 21-hydroxylase deficiency. *Journal of Pediatric Endocrinology & Metabolism* 2003; 16(8): 1119-1130.
23. Kino T, Charmandari E, Chrousos GP. Basic and clinical implications of glucocorticoid action – Focus on development: Conference Proceedings. *Hormone and Metabolic Research* 2003; 35(10): 628-648.
24. Chrousos GP, Charmandari E, Kino T. Glucocorticoid action networks: An introduction to systems biology. *Journal of Clinical Endocrinology & Metabolism* 2004; 89(2): 563-564.
25. Weise M, Mehlinger SL, Drinkard B, Rawson E, Charmandari E, Hiroi M, Eisenhofer G, Yanovski J, Chrousos GP, Merke DP. Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glucose elevation in response to high intensity exercise. *Journal of Clinical Endocrinology & Metabolism* 2004; 89(2): 591-597.
26. Charmandari E, Kino T, Vottero A, Souvatzoglou E, Bhattacharyya N, Chrousos GP. Natural glucocorticoid receptor mutants causing generalized glucocorticoid resistance: molecular genotype, genetic transmission and clinical phenotype. *Journal of Clinical Endocrinology & Metabolism* 2004; 89(4): 1939-1949.
27. Charmandari E, Merke DP, Negro PJ, Keil MF, Martinez PE, Haim A, Gold PW, Chrousos GP. Endocrinologic and psychologic evaluation of 21-hydroxylase deficiency carriers and matched normal subjects: evidence for physical and/or psychologic vulnerability to stress. *Journal of Clinical Endocrinology & Metabolism* 2004; 89(5): 2228-2236.
28. Charmandari E, Kino T, Chrousos GP. Glucocorticoids and their actions. *Annals of the New York Academy of Sciences* 2004; 1024: 1-8.
29. Charmandari E, Kino T, Chrousos GP. Familial/Sporadic glucocorticoid resistance: Clinical phenotype and molecular mechanisms. *Annals of the New York Academy of Sciences* 2004; 1024: 168-181.
30. Weise M, Mehlinger SL, Drinkard B, Rawson E, Charmandari E, Chrousos GP, Merke DP. Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term high-intensity exercise. *Journal of Clinical Endocrinology & Metabolism* 2004; 89(8): 3670-3684.

31. Charmandari E, Brook CGD, Hindmarsh PC. Classic congenital adrenal hyperplasia and puberty. *European Journal of Endocrinology* 2004; 151 Suppl 3: U77-82.
32. Charmandari E, Chrousos GP, Ichijo T, Bhattacharyya N, Vottero A, Souvatzoglou E, Kino T. The human glucocorticoid receptor (GR)  $\beta$  isoform suppresses the transcriptional activity of GR $\alpha$  by interfering with formation of active coactivator complexes. *Molecular Endocrinology* 2005; 19(1): 52-64.
33. Kino T, DeMartino MU, Charmandari E, Outas T, Ichijo T, Pavlakis GN, Chrousos GP. The human immunodeficiency virus type-1 (HIV-1) accessory protein Vpr inhibits the effect of insulin on the Foxo subfamily of Forkhead transcription factors by interfering with their binding to 14-3-3 proteins: Potential clinical implications regarding the insulin resistance of HIV-1-infected patients. *Diabetes* 2005; 54(1): 23-31.
34. Charmandari E, Chrousos GP, Merke DP. Pituitary adenoma with adrenocorticotropin hypersecretion following bilateral adrenalectomy in a patient with classic 21-hydroxylase deficiency. *Journal of Pediatric Endocrinology & Metabolism* 2005; 18(1): 97-101.
35. Charmandari E, Tsigos C, Chrousos GP. Endocrinology of the stress response. *Annual Reviews of Physiology* 2005; 67: 259-284.
36. Charmandari E, Raji A, Kino T, Ichijo T, Tiulpakov A, Zachman K, Chrousos GP. A novel point mutation in the ligand-binding domain (LBD) of the human glucocorticoid receptor (hGR) causing generalized glucocorticoid resistance: The importance of C-terminus of hGR LBD in conferring transactivational activity. *Journal of Clinical Endocrinology & Metabolism* 2005; 90(6): 3696-3705.
37. Kino T, Liu SH, Charmandari E, Chrousos GP. Glucocorticoid receptor mutants demonstrate increased motility inside the nucleus of living cells: Time of fluorescence recovery after photobleaching (FRAP) is an integrated measure of receptor function. *Molecular Medicine* 2004; 10(7-12): 80-88.
38. Charmandari E, Kino T, Ichijo T, Zachman K, Alatsatianos A, Chrousos GP. Functional characterization of the natural human glucocorticoid receptor (hGR) mutants hGR $\alpha$ R477H and hGR $\alpha$ G679S associated with generalized glucocorticoid resistance. *Journal of Clinical Endocrinology & Metabolism* 2006; 91(4): 1535-1543.
39. Kino T, Souvatzoglou E, Charmandari E, Ichijo T, Driggers P, Mayers C, Alatsatianos A, Manoli I, Westphal H, Chrousos GP, Segars JH. RHO family guanine nucleotide exchange factor BRX couples extracellular signals to the glucocorticoid signaling system. *Journal of Biological Chemistry* 2006; 281(14): 9118-9126.
40. Charmandari E, Chrousos GP. Metabolic syndrome manifestations in classic congenital adrenal hyperplasia: Do they predispose to atherosclerotic cardiovascular disease and secondary polycystic ovary syndrome? *Annals of the New York Academy of Sciences* 2006; 1083: 37-53.
41. Leong GM, Abad V, Charmandari E, Reynolds JC, Hill S, Chrousos GP, Nieman LK. Effects of child- and adolescent-onset endogenous Cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood. *Journal of Bone and Mineral Research* 2007; 22(1): 110-118.

42. Charmandari E, Kino T. Novel causes of generalized glucocorticoid resistance. *Hormone and Metabolic Research* 2007; 39(6): 445-450.
43. Charmandari E, Kino T, Ichijo T, Jubiz W, Mejia L, Zachman K, Chrousos GP. A novel point mutation in helix11 of the ligand-binding domain of the human glucocorticoid receptor gene causing generalized glucocorticoid resistance. *Journal of Clinical Endocrinology & Metabolism* 2007; 92(10): 3986 - 90.
44. Charmandari E, Kino T, Ichijo T, Chrousos GP. Generalized Glucocorticoid Resistance: Clinical aspects, molecular mechanisms and implications of a rare genetic disorder. *Journal of Clinical Endocrinology & Metabolism* 2008; 93(5): 1563-72.
45. Kino T, Ichijo T, Zachman K, Chrousos GP, Charmandari E. A novel point mutation in the amino terminal domain of the human glucocorticoid receptor (hGR) gene enhancing hGR-mediated gene expression. *Journal of Clinical Endocrinology & Metabolism* 2008; 93(12): 4963-8.
46. Chrousos GP, Kino T, Charmandari E. Evaluation of the hypothalamic-pituitary-adrenal axis function in childhood and adolescence. *Neuroimmunomodulation* 2009; 16(5): 272-283.
47. Charmandari E, Chrousos GP, Kino T. Identification of natural human glucocorticoid receptor (hGR) mutations or polymorphisms and their functional consequences at the hormone-receptor interaction level. *Methods in Molecular Biology* 2009; 590:33-60.
48. Nicolaides N, Galata Z, Chrousos GP, Charmandari E. The glucocorticoid receptor: Evolution, structure and molecular basis of biologic function. *Steroids* 2010; 75(1): 1-12.
49. Charmandari E, Kino T. Chrousos Syndrome: A seminal report, a phylogenetic enigma and the clinical implications of glucocorticoid signaling changes. *European Journal of Clinical Investigation* 2010; 40(10): 932-42.
50. Galata Z, Moschonis G, Makridakis M, Dimitraki P, Nicolaides N, Manios Y, Bartzeliotou A, Chrousos GP, Charmandari E. Plasma proteomic analysis in overweight and obese children. *European Journal of Clinical Investigation* 2011; 41(12): 1275-83.
51. Charmandari E. Primary generalized glucocorticoid resistance and hypersensitivity. *Hormone Research* 2011; 76(3): 145-55.
52. Charmandari E, Chrousos GP, Lambrou GI, Pavlaki A, Koide H, Ng SSM, Kino T. Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man. *PLoS One* 2011; 6(9): e25612.
53. Kino T, Charmandari E, Chrousos GP. Glucocorticoid receptor: Implications for rheumatic diseases. *Clinical and Experimental Rheumatology*, 2011; 29(5 Suppl 68): S32-41.
54. Charmandari E, Sertedaki A, Kino T, Merakou C, Hoffman DA, Hatch MM, Hurt DE, Lin L, Xekouki P, Stratakis CA, Chrousos GP. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. *Journal of Clinical Endocrinology & Metabolism* 2012; 97(8): E1532-9.

55. Moschonis G, Chrousos GP, Lionis C, Mougios V, Manios Y; Healthy Growth Study group (Charmandari E). Association of total body and visceral fat mass with iron deficiency in preadolescents: the Healthy Growth Study. *British Journal of Nutrition* 2012; 108(4): 710-9.
56. Charmandari E. Primary generalized glucocorticoid resistance and hypersensitivity: the end-organ involvement in the stress response. *Science Signaling* 2012; 5(244): pt5.
57. Charmandari E, Achermann JC, Carel JC, Soder O, Chrousos GP. Stress response and child health. *Science Signaling* 2012; 5(248): mr1.
58. Birbilis M, Moschonis G, Mougios V, Manios Y; Healthy Growth Study' group (Charmandari E). Obesity in adolescence is associated with perinatal risk factors, parental BMI and sociodemographic characteristics. *European Journal of Clinical Nutrition* 2013; 67(1): 115-21.
59. Charmandari E, Kino T, Chrousos G. Primary generalized glucocorticoid resistance (Chrousos syndrome) and hypersensitivity. *Endocrine Development* 2013; 24: 67-85.
60. Peters CJ, Hill N, Dattani MT, Charmandari E, Matthews DR, Hindmarsh PC. Deconvolution analysis of 24h serum cortisol profiles informs the amount and distribution of hydrocortisone replacement therapy. *Clinical Endocrinology (Oxford)* 2013; 78(3): 347-51.
61. Roberts ML, Kino T, Nicolaides NC, Hurt DE, Katsantoni E, Sertedaki A, Komianou F, Kassiou K, Chrousos GP, Charmandari E. A novel point mutation in the DNA-Binding Domain (DBD) of the human glucocorticoid receptor causes Primary Generalized Glucocorticoid Resistance by disrupting the hydrophobic structure of its DBD. *Journal of Clinical Endocrinology & Metabolism* 2013; 98(4): E790-5.
62. Manios Y, Birbilis M, Moschonis G, Birbilis G, Mougios V, Lionis C, Chrousos GP; 'Healthy Growth Study' group (Charmandari E). Childhood obesity risk evaluation based on perinatal factors and family sociodemographic characteristics: CORE index. *European Journal of Pediatrics* 2013; 172(4): 551-5.
63. Androutsos O, Moschonis G, Koumpitski A, Mantzou A, Roma-Giannikou E, Chrousos GP, Manios Y, Kanaka-Gantenbein C; "Healthy Growth Study" Group (Charmandari E). The correlation of right 2D: 4D finger length ratio to the low-grade inflammation marker IL-6 in children. The Healthy Growth Study. *Early Human Development* 2014; 90(1): 61-5.
64. Nicolaides NC, Roberts ML, Kino T, Braatvedt G, Hurt DE, Katsantoni E, Sertedaki A, Chrousos GP, Charmandari E. A novel point mutation of the human glucocorticoid receptor gene causes Primary Generalized Glucocorticoid Resistance through impaired interaction with the LXXLL motif of the p160 coactivators: Dissociation of the transactivating and transrepressive activities. *Journal of Clinical Endocrinology & Metabolism* 2014; 99(5): E902-7.
65. Manios Y, Moschonis G, Papandreou C, Siatitsa PE, Iatridi V, Lidoriki I, Lionis C, Chrousos GP; Healthy Growth Study group (Charmandari E). Female sex, small size at birth and low family income increase the likelihood of insulin resistance in late childhood: the Healthy Growth Study. *Pediatric Diabetes* 2014; 15(1): 41-50.

66. Moschonis G, Kalliora AC, Costarelli V, Papandreou C, Koutoukidis D, Lionis C, Chrousos GP, Manios Y; Healthy Growth Study Group (Charmandari E). Identification of lifestyle patterns associated with obesity and fat mass in children: the Healthy Growth Study. *Public Health Nutrition* 2014; 17(3): 614-24.
67. Nicolaides N, Charmandari E, Chrousos GP, Kino T. Circadian Endocrine Rhythms: HPA Axis and its actions. *Annals of the New York Academy of Sciences* 2014; 1318: 71-80.
68. Charmandari E, Nicolaides N, Chrousos GP. Adrenal Insufficiency. *Lancet* 2014; 383(9935): 2152-67.
69. Nicolaides NC, Charmandari E, Chrousos GP, Kino T. Recent advances in the molecular mechanisms determining tissue sensitivity to glucocorticoids: novel mutations, circadian rhythm and ligand-induced repression of the human glucocorticoid receptor. *BMC Endocrine Disorders* 2014; 14: 71.
70. Nicolaides N, Kyratzi E, Lamprokostopoulou A, Chrousos G, Charmandari E. Stress, stress system and the role of glucocorticoids. *Neuroimmunomodulation* 2015; 22(1-2): 6-19.
71. Hindmarsh PC, Charmandari E. Variation in absorption and half-life of hydrocortisone influence on plasma cortisol concentrations. *Clinical Endocrinology (Oxford)* 2015; 82(4): 557-61.
72. Nicolaides NC, Charmandari E. Chrousos syndrome: from molecular pathogenesis to therapeutic management. *European Journal of Clinical Investigation* 2015; 45(5): 504-14.
73. Markou A, Sertedaki A, Kaltsas G, Androulakis I, Marakaki C, Pappa T, Gouli A, Papanastasiou L, Fountoulakis S, Zacharoulis A, Karavidas A, Ragkou D, Charmandari E, Chrousos GP, Piaditis GP. Stress-induced aldosterone hypersecretion in a substantial subset of patients with essential hypertension. *Journal of Clinical Endocrinology & Metabolism* 2015; 100(8): 2857-64.
74. Nicolaides NC, Geer EB, Vlachakis D, Roberts ML, Psarra AG, Moutsatsou P, Sertedaki A, Kossida S, Charmandari E. A novel mutation of the hGR gene causing Chrousos syndrome. *European Journal of Clinical Investigation* 2015; 45(8): 782-91.
75. Nicolaides NC, Lamprokostopoulou A, Polyzos A, Kino T, Katsantoni E, Triantafyllou P, Christophoridis A, Katzos G, Dracopoulou M, Sertedaki A, Chrousos GP, Charmandari E. Transient Generalized Glucocorticoid Hypersensitivity. *European Journal of Clinical Investigation* 2015; 45(12): 1306-15.
76. Charmandari E, Zhang RG, Silveira LG, Fan QR, Chrousos GP, Sertedaki A, Latronico AC, Segaloff DL. Misfolding Ectodomain Mutations of the Lutropin Receptor Increase Efficacy of Hormone Stimulation. *Molecular Endocrinology* 2016; 30(1): 62-76.
77. Stavrou S, Nicolaides NC, Papageorgiou I, Papadopoulou P, Terzioglou E, Darviri C, Chrousos GP, Charmandari E. The effectiveness of a stress-management intervention program in the management of overweight and obesity in childhood and adolescence. *Journal of Molecular Biochemistry* 2016; 5(2): 63-70.

78. Nicolaides NC, Lamprokostopoulou A, Sertedaki A, Charmandari E. Recent Advances in the Molecular Mechanisms Causing Primary Generalized Glucocorticoid Resistance. *Hormones (Athens)* 2016; 15(1): 23-34.
79. Lee PA, Nordenström A, Houk CP, Ahmed SF, Auchus R, Baratz A, Baratz Dalke K, Liao LM, Lin-Su K, Looijenga LH 3rd, Mazur T, Meyer-Bahlburg HF, Mouriquand P, Quigley CA, Sandberg DE, Vilain E, Witchel S; Global DSD Update Consortium (Charmandari E). Global Disorders of Sex Development Update since 2006: Perceptions, Approach and Care. *Horm Res Paediatr*. 2016; 85(3): 158-80.
80. Nicolaides NC, Skyrila E, Vlachakis D, Psarra AG, Moutsatsou P, Sertedaki A, Kossida S, Charmandari E. Functional Characterization of the hGR $\alpha$ T556I Causing Chrousos Syndrome. *European Journal of Clinical Investigation* 2016; 46(1): 42-9.
81. Hurt DE, Suzuki S, Mayama T, Charmandari E, Kino T. Structural Analysis on the Pathologic Mutant Glucocorticoid Receptor Ligand-binding Domains. *Molecular Endocrinology* 2016; 2016; 30(2): 173-88.
82. Kassi E, Semaniakou A, Sertedaki A, Evangelopoulos ME, Kazazoglou T, Kominakis A, Sfagos C, Charmandari E, Chrousos GP, Moutsatsou P. Sequencing analysis of the human glucocorticoid receptor (NR3C1) gene in multiple sclerosis patients. *Journal of Neurological Science* 2016; 363: 165-9.
83. Sertedaki A, Markou A, Vlachakis D, Kossida S, Campanac E, Hoffman DA, Sierra ML, Xekouki P, Stratakis CA, Kaltsas G, Piaditis GP, Chrousos GP, Charmandari E. Functional characterization of two novel germline mutations of the KCNJ5 gene in hypertensive patients without primary aldosteronism but with ACTH-dependent aldosterone hypersecretion. *Clinical Endocrinology (Oxford)* 2016; 85(6): 845-851.
84. Nicolaides NC, Kino T, Roberts ML, Katsantoni E, Sertedaki A, Moutsatsou P, Psarra AG, Chrousos GP, Charmandari E. The role of S-palmitoylation of the human glucocorticoid receptor (hGR) in mediating the nongenomic glucocorticoid actions. *Journal of Molecular Biochemistry* 2017; 6(1): 3-12.
85. Papageorgiou L, Vlachakis C, Dragoumani K, Raftopoulou S, Brouzas D, Nicolaides NC, Chrousos GP, Charmandari E, Megalooikonomou V, Vlachakis D. HCV genetics and genotypes dictate future antiviral strategies. *Journal of Molecular Biochemistry* 2017; 6: 33-40.
86. Kyritsi EM, Koltsida G, Farakla I, Papanikolaou A, Critselis E, Mantzou E, Zoumakis E, Kolaitis G, Chrousos GP, Charmandari E. Psychological vulnerability to stress in carriers of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Hormones (Athens)*. 2017; 16(1): 42-53.
87. Stavrou S, Nicolaides NC, Critselis E, Darviri C, Charmandari E, Chrousos GP. Paediatric stress: from neuroendocrinology to contemporary disorders. *European Journal of Clinical Investigation* 2017; 47(3): 262-269.
88. Nicolaides NC, Charmandari E. Novel insights into the molecular mechanisms underlying generalized glucocorticoid resistance and hypersensitivity syndromes. *Hormones (Athens)*. 2017; 16(2): 124-138.



89. Nicolaides NC, Charmandari E, Kino T, Chrousos GP. Stress-related and circadian secretion and target tissue actions of glucocorticoids: Impact on health. *Frontiers in Endocrinology (Lausanne)*. 2017; 8:70.
90. Bacopoulou F, Kolias E, Efthymiou V, Antonopoulos CN, Charmandari E. Vitamin D predictors in polycystic ovary syndrome: A meta-analysis. *European Journal of Clinical Investigation* 2017; 47(10): 746-755.
91. Al-Daghri NM, Batzel JJ, Burgmann H, Carbone F, Charmandari E, Chrousos GP, Distelmaier K, Cvirn G, Dullaart RPF, Dumitrascu DL, Esteve-Pastor MA, Gervasini G, Goliasch G, Goswami N, Gruppen EG, Hernández-Mijares A, Kalantaridou SN, Krause R, Latini R, Makrigiannakis A, Marín F, Masson S, Montecucco F, Ndrepepa G, Nicolaides NC, Novelli D, Orasan OH, Qorbani M, Ratzinger F, Roessler A, Sabico S, Sciatti E, Stefanaki C, Stoner L, Tabatabaei-Malazy O, Tatar E, Toz H, Uslu A, Victor VM, Vizzard E. Research update for articles published in EJCI in 2015. *European Journal of Clinical Investigation* 2017; 47(10): 775-788.
92. Vardas K, Ilia S, Sertedaki A, Charmandari E, Briassouli E, Goukos D, Apostolou K, Psarra K, Botoula E, Tsagarakis S, Magira E, Routsis C, Stratakis CA, Nanas S, Briassoulis G. Increased glucocorticoid receptor expression in sepsis is related to heat shock proteins, cytokines, and cortisol and is associated with increased mortality. *Intensive Care Medicine Experimental* 2017; 5(1): 10.
93. Kassari P, Papaioannou P, Billiris A, Karanikas H, Eleftheriou S, Thireos E, Manios Y, Chrousos GP, Charmandari E. Electronic Registry for the Management of Childhood Obesity in Greece. *European Journal of Clinical Investigation* 2018; 48(3). doi: 10.1111/eci.12887.
94. Emmanouil CC, Pervanidou P, Charmandari E, Darviri C, Chrousos GP. The effectiveness of a health promotion and stress-management intervention program in a sample of obese children and adolescents. *Hormones (Athens)*. 2018; 17(3): 405-413.
95. Adlbrecht C, Blanco-Verea A, Bouzas-Mosquera MC, Brion M, Burtscher M, Carbone F, Chang TT, Charmandari E, Chen JW, Correia-Costa L, Dullaart RPF, Eleftheriades M, Fernandez-Fernandez B, Goliasch G, Gremmel T, Groeneveld ME, Henrique A, Huelsmann M, Jung C, Lichtenauer M, Montecucco F, Nicolaides NC, Niessner A, Palmeira C, Pirklbauer M, Sanchez-Niño MD, Sotiriadis A, Sousa T, Sulzgruber P, van Beek AP, Veronese N, Winter MP, Yeung KK, Bouzas-Mosquera A. Research update for articles published in EJCI in 2016. *European Journal of Clinical Investigation* 2018; 48(10): e13016. doi: 10.1111/eci.13016.
96. Katsarou MS, Karathanasopoulou A, Andrianopoulou A, Desiniotis V, Tzinis E, Dimitrakis E, Lagiou M, Charmandari E, Aschner M, Tsatsakis AM, Chrousos GP, Drakoulis N. Beta 1, Beta 2 and Beta 3 Adrenergic Receptor Gene Polymorphisms in a Southeastern European Population. *Frontiers in Genetics* 2018; 9:560.
97. Krishna KB, Fuqua JS, Popovic J, Rogol AD, Houk CP, Charmandari E, Lee PA. Use of Gonadotropin-Releasing Hormone Analogs (GnRHa) in Children: Update by an International Consortium. *Hormone Research in Paediatrics* 2019; 91(6): 357-372.
98. Nicolaides NC, Charmandari E. Glucocorticoid Resistance. *Exp Suppl.* 2019; 111:85-102.

99. Polytarchou A, Katsouli G, Tsaoussoglou M, Charmandari E, Kanaka-Gantenbein C, Chrousos G, Kадitis AG. Obstructive events in children with Prader-Willi syndrome occur predominantly during rapid eye movement sleep. *Sleep Medicine* 2018; 54: 43-47.
100. Farakla I, Kouli E, Arditi J, Papageorgiou I, Bartzeliотou A, Papadopoulos GE, Mantzou A, Papathanasiou C, Dracopoulou M, Papastamataki M, Moutsatsou P, Papassotiriou I, Chrousos GP, Charmandari E. Effect of honey on glucose and insulin concentrations in obese girls. *European Journal of Clinical Investigation* 2019; 49(2): e13042.
101. Moschonis G, Michalopoulou M, Tsoutsouloupoulou K, Vlachopapadopolou E, Michalacos S, Charmandari E, Chrousos GP, Manios Y. Assessment of the Effectiveness of a Computerised Decision-Support Tool for Health Professionals for the Prevention and Treatment of Childhood Obesity. Results from a Randomised Controlled Trial. *Nutrients*. 2019; 11(3). pii: E706.
102. Gray LJ, Brady EM, Albaina O, Edwardson CL, Harrington D, Khunti K, Miksza J, Raposo JF, Smith E, Vazeou A, Vergara I, Weihrauch-Blüher S, Davies MJ; PRE-STARt Collaborative (Charmandari E). Evaluation and refinement of the PRESTARt tool for identifying 12-14 year olds at high lifetime risk of developing type 2 diabetes compared to a clinicians assessment of risk: a cross-sectional study. *BMC Endocrine Disorders* 2019; 19(1): 79.
103. Nicolaides NC, Polyzos A, Koniari E, Lamprokostopoulou A, Papageorgiou I, Golfinopoulou E, Papathanasiou C, Sertedaki A, Thanos D, Chrousos GP, Charmandari E. Transcriptomics in tissue glucocorticoid sensitivity. *European Journal of Clinical Investigation* 2019; e13129.
104. Arellano-Orden E, Bacopoulou F, Baicus C, Bonfrate L, Broadbent J, Buechler C, Carbone F, Charmandari E, Davis GR, Dullaart RPF, Efthymiou V, Goeser F, Goswami N, Jong GP, Lichtenauer M, Liou YS, Lutz P, Maeng M, Mert GÖ, Mert KU, Montecucco F, Ndrepepa G, Olesen KKW, Oliveira P, Pertou FG, Portincasa P, Rodriguez-Panadero F, Scherthaner C, Schutte R. Research update for articles published in EJCI in 2017. *European Journal of Clinical Investigation* 2019; 49(10): e13163.
105. Lamprokostopoulou A, Moschonis G, Manios Y, Critselis E, Nicolaides NC, Stefa A, Koniari E, Gagos S, Charmandari E. Childhood obesity and leukocyte telomere length. *European Journal of Clinical Investigation* 2019; e13178. doi: 10.1111/eci.13178. [Epub ahead of print].
106. Stefa A, Lamprokostopoulou A, Briana D, Kontogeorgou A, Papageorgiou I, Malamitsi-Puchner A, Tsitsilonis O, Gagos S, Charmandari E. The effect of intrauterine growth on leukocyte telomere length at birth. *Journal of Maternal-Fetal & Neonatal Medicine* 2018; 6: 1-6.

#### **Publications in non-SCI Journals**

107. Charmandari E. Phytoestrogens and child health. *Clinicae Paediatricae Universitatis Atheniensis* 2008; 55(3): 252-258.

108. Chrousos GP, Kino T, Charmandari E. Generalized glucocorticoid resistance. *European Endocrinology* 2008; 4(2): 93-99.
109. Charmandari E. Glucocorticoids. *Pediatrici* 2009; 72(3): 161-173.
110. Charmandari E. Precocious Puberty. *Pediatrici* 2010; 73(3): 81-89.
111. Charmandari E. Chrousos Syndrome. *Clinicae Paediatricae Universitatis Atheniensis* 2011; 58(4): 293-305.
112. Charmandari E. Prevention and management of obesity in childhood and adolescence. *Clinicae Paediatricae Universitatis Atheniensis* 2013; 60(1): 50-54.
113. Charmandari E. National program on the prevention and management of overweight and obesity in childhood and adolescence. *Clinicae Paediatricae Universitatis Atheniensis* 2013; 60(2): 131-132.
114. Charmandari E. Gender Dysphoria: Consensus Guidelines of the Endocrine Society. *Clinicae Paediatricae Universitatis Atheniensis* 2018; (in press).

## **B. Books**

1. Charmandari E, Chrousos GP. *Adrenal Insufficiency*. In Encyclopedia of Endocrine Diseases. Luciano Martini (ed), Elsevier, San Diego, CA, USA. 2004; pages 75-80.
2. Charmandari E, Kino T, Chrousos GP. *Glucocorticoid Receptor*. In Encyclopedia of Endocrine Diseases. Luciano Martini (ed), Elsevier, San Diego, CA, USA. 2004; pages 229-234.
3. Charmandari E, Chrousos GP. *Glucocorticoids, Overview*. In: Encyclopedia of Endocrine Diseases. Luciano Martini (ed), Elsevier, San Diego, CA, USA. 2004; pages 253-259.
4. Charmandari E, Kino T, Chrousos GP. *Glucocorticoids*. In Neonatal and Pediatric Pharmacology, 3<sup>rd</sup> Edition. Yaffe SJ and Aranda JV (eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA. 2004; pages 713-726.
5. Kino T, Charmandari E, Chrousos GP. *Glucocorticoid action - Basic and clinical implications*. Annals of the New York Academy of Sciences 2004; Volume 1024; pages 1-221.
6. Charmandari E, Chrousos GP, Merke DP. *Classic Congenital Adrenal Hyperplasia*. In Adrenal Glands: Diagnostic Aspects and Surgical Therapy. Linos DA and van Heerden JA (eds) Springer-Verlag, Germany, 2005; Chapter 10, pages 101-114.
7. Charmandari E, Kino T, Chrousos GP. *Generalized Glucocorticoid Insensitivity: Clinical Phenotype and Molecular Mechanisms*. In Overcoming Steroid Insensitivity in Respiratory Disease. Adcock I and Chung F (eds), John Wiley & Sons, Ltd, United Kingdom, 2008; Chapter 5, pages 73-87.
8. Charmandari E. *Puberty and Adrenarche*. In Reproductive Endocrinology. Mastorakos G (eds) 2008; Chapter 21 (in press).

9. Charmandari E, Chrousos GP, Kino T. *Identification of Natural Human Glucocorticoid Receptor (hGR) Mutations or Polymorphisms and their Functional Consequences at the Hormone-Receptor Interaction Level*. In *Methods in Molecular Biology - Molecular Endocrinology: A Comprehensive Guide to Current Methodologies*. Sarge OP and Curry T (eds), Humana Press, USA, 2009; Chapter 3, pages 33-60.
10. Charmandari E, Kino T, Chrousos GP. *Glucocorticoids*. In *Neonatal and Pediatric Pharmacology*, 4<sup>th</sup> Edition. Yaffe SJ and Aranda JV (eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA. 2010; Chapter 51, pages: 760-772.
11. van den Akker ELT, Charmandari E. *Adrenals*. In *Yearbook of Pediatric Endocrinology*, JC Carel, Z Hochberg (eds), Karger AG, Basel, Switzerland, 2010; Pages 99-118.
12. Kino T, Charmandari E, Chrousos GP. *Disorders of the hypothalamic-pituitary- adrenocortical system*. In *Handbook of Neuroendocrinology*. George Fink, Donald Pfaff and Jon Levine (eds), Elsevier, San Diego, California, USA, 2011, Chapter IV, Pages 639-658.
13. van den Akker ELT, Charmandari E. *Adrenals*. In *Yearbook of Pediatric Endocrinology*, JC Carel, Z Hochberg (eds), Karger AG, Basel, Switzerland, 2011; Pages 99-119.
14. van den Akker ELT, Charmandari E. *Adrenals*. In *Yearbook of Pediatric Endocrinology*, Ken Ong, Z Hochberg (eds), Karger AG, Basel, Switzerland, 2012; Pages: 99-115.
15. Charmandari E, Chrousos GP. Primary Generalized Glucocorticoid Resistance or Chrousos syndrome. In *Oxford Desk Reference - Endocrinology*, Helen Turner, Ashley Grossman and Richard Eastell (eds), Oxford University Press, Oxford, UK; 2012 (in press).
16. Charmandari E, Chrousos GP. The Effect of Stress on the Hypothalamic-pituitary-adrenal Axis: An Update. In *Neuroendocrine Disorders in Children*, Mehul T. Dattani (Editor), McKeith Press, London, UK; 2012 (in press).
17. Charmandari E. Precocious Puberty. In: *Pediatric and Adolescent Primary Health Care*. Chrysanthopoulos C (ed), Rotonda, Thessaloniki, Greece, 2012; Pages: 419-425.
18. Charmandari E. Delayed Puberty. In: *Pediatric and Adolescent Primary Health Care*. Chrysanthopoulos C (ed), Rotonda, Thessaloniki, Greece, 2012; Pages: 425-428.
19. Charmandari E, Kino T, Chrousos GP. Primary Generalized Glucocorticoid Resistance and Hypersensitivity. In *Endocrine Hypertension*, Koch CA, Chrousos GP (eds), Springer, Humana Press, USA, 2013; Pages 69-87.
20. Charmandari E, Kino T, Chrousos GP. Primary Generalized Familial and Sporadic Glucocorticoid Resistance (Chrousos syndrome) and Hypersensitivity. In *Endocrine Development*, Maghnie M (ed); 2013, Volume 24, Pages: 67–85.
21. Pervanidou P, Charmandari E, Chrousos GP. Endocrine aspects of childhood obesity. *Current Pediatric Reports*, Ronald Kleinman (Editor), Springer Science & Business Media, New York, NY, USA; 2013; 109-117.

22. van den Akker ELT, Charmandari E. *Adrenals*. In Yearbook of Pediatric Endocrinology, JC Carel, Z Hochberg (eds), Karger AG, Basel, Switzerland, 2013; Pages: 97-111.
23. Nicolaides NC, Charmandari E, Chrousos GP. Adrenal Steroid Hormone Secretion: Physiologic and Endocrine Aspects. In Encyclopedia of Human Biology, 3rd edition, 2014 (in press).
24. van den Akker ELT, Charmandari E. *Adrenals*. In Yearbook of Pediatric Endocrinology, K Ong, Z Hochberg (eds), Karger AG, Basel, Switzerland, 2014; 97-114.
25. Nicolaides NC, Charmandari E, Chrousos GP. The hypothalamic-pituitary-adrenal axis in human health and disease. In: Introduction to Translational Cardiovascular Research, Cokkinos D (ed), 2015, Pages: 91-107.
26. van den Akker ELT, Charmandari E. *Adrenals*. In Yearbook of Pediatric Endocrinology, K Ong, Z Hochberg (eds), Karger AG, Basel, Switzerland, 2015; Pages: 97-114.
27. Nicolaides NC, Chrousos GP, Charmandari E. Chrousos Syndrome: From molecular pathogenesis to diagnostic and therapeutic approach. In: Publication in honor of emeritus Professor Emmanuel Kanavakis, Kitsiou S & Mavrou A (editors), Broken Hill Publishers Ltd, Nicosia, Cyprus, 2016; Pages: 553-564.
28. van den Akker ELT, Charmandari E. *Adrenals*. In Yearbook of Pediatric Endocrinology, K Ong, Z Hochberg (eds), Karger AG, Basel, Switzerland, 2016; Pages: 97-112.
29. Kyritsi EM, Kourkouti C, Chrousos GP, Charmandari E. Hypercortisolism and Cushing Syndrome. In Biomedical Sciences 2016.
30. Charmandari E, Kyritsi EM, Stratakis C, Sarafoglou K, Chrousos GP. Cushing syndrome in childhood and adolescence. In: Pediatric Endocrinology and Inborn Errors of Metabolism, Sarafoglou K, Hoffmann GF, Roth KS (eds), McGraw Hill, New York, NY 10121, USA; 2017, Part IV, Pages: 561-576.
31. Nicolaides NC, Lamprokostopoulou A, Sertedaki A, Chrousos GP, Charmandari E. Primary Generalized Glucocorticoid Resistance or Chrousos Syndrome: Allostasis through a Mutated Glucocorticoid Receptor. In: The Hypothalamic Pituitary Adrenal Axis in Health and Disease, Geer E (eds), Springer, New York, NY 10110, USA, 2017; Pages 255-269.
32. Flueck C, Charmandari E. *Adrenals*. In Yearbook of Pediatric Endocrinology, K Ong, Z Hochberg (eds), Karger AG, Basel, Switzerland, 2017; (in press).
33. Kassari P, Papaioannou P, Billiris A, Karanikaw H, Eleftheriou S, Thireos E, Manios Y, Chrousos GP, Charmandari E. E-Health: National registry for the prevention and management of of overweight and obesity in childhood and adolescence. In: Publication in honor of emeritus Professor Anagnostopoulos 2017 (in press).
34. Nicolaides NC, Charmandari E. Adrenal Insufficiency: Etiology and Diagnosis. In: Encyclopedia of Endocrine Diseases. Ilpo Huhtaniemi, Luciano Martini & Andre Lacroix (eds), Elsevier, San Diego, CA, USA; 2017 (in press).

35. Nicolaides NC, Charmandari E, Chrousos GP. Glucocorticoids-Overview. In: Encyclopedia of Endocrine Diseases. Ilpo Huhtaniemi, Luciano Martini & Andre Lacroix (eds), Elsevier, San Diego, CA, USA; 2018 (in press).
36. Flueck C, Charmandari E. Adrenals. In Yearbook of Pediatric Endocrinology, K Ong, Z Hochberg (eds), Karger AG, Basel, Switzerland, 2018; (in press).
37. Nicolaides NC, Charmandari E. Glucocorticoid Resistance. In Genetics of Endocrine Diseases and Syndromes. Peter Igaz & Attila Patócs (eds), Springer Nature, Switzerland, 2019; (in press).
38. Lajic S, Karlsson L, Charmandari E. Adrenals. In Yearbook of Pediatric Endocrinology, K Ong, Z Hochberg (eds), Karger AG, Basel, Switzerland, 2019; (in press).

### C. Electronic Books and Journals

39. Kino T, Charmandari E, Chrousos GP. Glucocorticoids: synthesis, action, physiology. In Endotext: Adrenal Disease and Function. Leslie DeGroot (ed). 2003; Chapter 2; [www.Endotext.org](http://www.Endotext.org).
40. Kino T, Charmandari E, Chrousos GP. Glucocorticoid Receptor. In Endotext: Adrenal Disease and Function. Leslie DeGroot (ed). 2003; Chapter 6; [www.Endotext.org](http://www.Endotext.org).
41. Charmandari E, Chrousos GP. Adrenal insufficiency. In Endotext: Adrenal Disease and Function. Leslie DeGroot (ed). 2003; Chapter 13; [www.Endotext.org](http://www.Endotext.org).
42. Charmandari E, Kino T, Chrousos GP. Glucocorticoid resistance syndrome. In Pediatric Medicine, Endocrinology. Neish SR (ed). 2003; [www.eMedicine.com](http://www.eMedicine.com).
43. Charmandari E, Kino T, Chrousos GP. Familial/Sporadic glucocorticoid resistance. In Orpha.net 2004; [www.orpha.net](http://www.orpha.net).
44. Charmandari E, Kino T, Chrousos GP. Molecular mechanisms of glucocorticoid action. In Orpha.net 2004; [www.orpha.net](http://www.orpha.net).
45. Kino T, Charmandari E, Chrousos GP. Glucocorticoid Receptor. In Endotext: Adrenal Disease and Function. Leslie DeGroot (ed). 2010; [www.Endotext.org](http://www.Endotext.org).
46. Kino T, Vottero A, Charmandari E. Primary Generalized Glucocorticoid Resistance or Chrousos syndrome. In Endotext: Adrenal Disease and Function. Leslie DeGroot (ed). 2010; [www.Endotext.org](http://www.Endotext.org).
47. Charmandari E, Kino T, Chrousos GP. Primary Generalized Familial and Sporadic Glucocorticoid Resistance (Chrousos syndrome). In Pediatric Medicine, Endocrinology. Neish SR (ed). 2011; [www.eMedicine.com](http://www.eMedicine.com).
48. Nicolaides N, Charmandari E, Chrousos GP. Adrenal insufficiency. In Endotext: Adrenal Disease and Function. Leslie DeGroot (ed). 2011; [www.Endotext.org](http://www.Endotext.org).

49. Karaflou M, Charmandari E, Sertedaki A, Chrousos GP. Familial or sporadic adrenal hypoplasia syndromes. In Endotext: Adrenal Disease and Function. Leslie DeGroot (ed). 2011; [www.Endotext.org](http://www.Endotext.org).
50. Charmandari E, Kino T, Chrousos GP. Primary Generalized Glucocorticoid Resistance syndrome. In Pediatric Medicine, Endocrinology. Neish SR (ed). 2013; [www.eMedicine.com](http://www.eMedicine.com).
51. Nicolaides NC, Chrousos GP, Charmandari E. Adrenal Insufficiency. Leslie DeGroot (ed). 2013; [www.Endotext.org](http://www.Endotext.org).
52. Nicolaides NC, Kino T, Chrousos GP, Charmandari E. Primary Generalized Glucocorticoid Resistance or Chrousos syndrome. Leslie DeGroot (ed). 2014; [www.Endotext.org](http://www.Endotext.org).
53. Kyritsi EM, Sertedaki A, Chrousos GP, Charmandari E. Familial or sporadic adrenal hypoplasia syndromes. In Endotext: Adrenal Disease and Function. Leslie DeGroot (ed). 2015; [www.Endotext.org](http://www.Endotext.org).
54. Nicolaides NC, Charmandari E. Chrousos syndrome. In Bio: Bio Health. M. Theodorakis (ed). 2015; [www.biomagazine.gr](http://www.biomagazine.gr) (<http://www.biomagazine.gr/index.php/site/article/39/2/BIO%20Health/to-syndromo-xroysos-kai-h-therapeytikh-proseggish>)
55. Nicolaides NC, Kino T, Chrousos GP, Charmandari E. Primary Generalized Glucocorticoid Resistance or Chrousos syndrome. Leslie DeGroot (ed). 2017; [www.Endotext.org](http://www.Endotext.org).
56. Nicolaides NC, Kino T, Chrousos GP, Charmandari E. Adrenal Insufficiency. Leslie DeGroot (ed). 2017; [www.Endotext.org](http://www.Endotext.org).

## 10. PUBLICATIONS IN CONFERENCE PROCEEDINGS

---

### A/ PUBLICATIONS IN INTERNATIONAL CONFERENCE PROCEEDINGS

1. Charmandari E, Koziell A, Hindmarsh PC, Scambler P, Brook CGD. (1998) Intersex disorders and the Wilms' Tumor suppressor gene: **Poster presentation** at the 37<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Florence, Italy.
2. Charmandari E. (1998) A difficult case of Cushing's disease. **Oral presentation** at the Clinicopathological Conference on Pituitary Disease, London, UK.
3. Charmandari E, Hindmarsh PC, Brook CGD, Scambler P, Koziell A. (1999) Mutations in the Wilms' Tumour suppressor gene are responsible for Frasier syndrome. **Oral presentation** at the 18<sup>th</sup> joint Meeting of the British Endocrine Societies, Bournemouth, UK.
4. Charmandari E, Hindmarsh PC, Brook CGD. (2000) The half-life of intravenously administered hydrocortisone in prepubertal and pubertal patients with congenital adrenal hyperplasia. **Poster presentation** at the 19<sup>th</sup> joint Meeting of the British Endocrine Societies, Birmingham, UK.

5. Charmandari E, Hindmarsh PC, Lichtarowicz-Krynska E, Brook CGD, Aynsley-Green A. (2000) What is achieved with conventional cortisol replacement regimens in children with congenital adrenal hyperplasia. **Plenary lecture** at the 4<sup>th</sup> Spring Meeting of the Royal College of Paediatrics and Child Health, York, UK.
6. Charmandari E, Dattani MT, Perry LA, Hindmarsh PC, Brook CGD. (2000) Kinetics and effect of percutaneous administration of dihydrotestosterone in children. **Oral presentation** at the Meeting of the British Society for Pediatric Endocrinology and Diabetes, Birmingham, UK.
7. Charmandari E, Hindmarsh PC, Johnston A, Brook CGD. (2000) Pharmacokinetics of intravenously administered hydrocortisone in prepubertal and pubertal patients with congenital adrenal hyperplasia. **Poster presentation** at the 82<sup>nd</sup> Endocrine Society Annual Meeting, Toronto, Canada.
8. Charmandari E, Hindmarsh PC, Johnston A, Brook CGD. (2000) Pharmacokinetics of intravenously administered hydrocortisone in adequately controlled patients with congenital adrenal hyperplasia. **Poster presentation** at the 38<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Brussels, Belgium.
9. Charmandari E, Hindmarsh PC, Johnston A, Brook CGD. (2000) The effect of flutamide treatment on cortisol pharmacokinetics in congenital adrenal hyperplasia. **Poster presentation** at the 38<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Brussels, Belgium.
10. Spoudeas HA, Charmandari E, Brook CGD. (2000) The effect of cranial irradiation for tumours distal to pituitary on ACTH secretion. **Oral presentation** at the 38<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Brussels, Belgium.
11. Hindmarsh PC, Charmandari E, Pincus SM, Matthews DR, Fall CHD, CGD Brook. (2001) Older females secrete growth hormone and cortisol more asynchronously than their male counterparts. **Poster presentation** at the 20<sup>th</sup> joint Meeting of the British Endocrine Societies, Belfast, Ireland.
12. Charmandari E, Johnston A, CGD Brook, Hindmarsh PC. (2001) Does adequacy of control of classical 21-hydroxylase deficiency alter feedback effects of cortisol at the pituitary level? **Poster presentation** at the 20<sup>th</sup> joint Meeting of the British Endocrine Societies, Belfast, Ireland.
13. Johnston A, Charmandari E, CGD Brook, Hindmarsh PC. (2001) The bioavailability of oral hydrocortisone in patients with classical 21-hydroxylase deficiency. **Poster presentation** at the 20<sup>th</sup> joint Meeting of the British Endocrine Societies, Belfast, Ireland.
14. Charmandari E, Matthews DR, Johnston A, CGD Brook, Hindmarsh PC. (2001) Serum cortisol and growth hormone inter-relation in patients with classical 21-hydroxylase deficiency. **Poster presentation** at the 20<sup>th</sup> joint Meeting of the British Endocrine Societies, Belfast, Ireland.
15. Charmandari E, Pincus SM, Matthews DR, Johnston A, Brook CGD, Hindmarsh PC. (2001) Joint growth hormone and cortisol secretion is more synchronous in children with classical 21-hydroxylase deficiency than in normal controls. **Poster presentation** at the 83<sup>rd</sup> Endocrine Society Annual Meeting, Denver, USA.



16. Charmandari E, Calis KA, Mohassel MR, Keil M, Chrousos GP, Merke DP. (2001) Flutamide treatment decreases cortisol clearance: implications for therapy of congenital adrenal hyperplasia. **Poster presentation** at the 83<sup>rd</sup> Endocrine Society Annual Meeting, Denver, USA.
17. Charmandari E, Johnston A, Matthews DR, Brook CGD, Hindmarsh PC. (2001) Serum cortisol and 17-hydroxyprogesterone inter-relation in patients with classical 21-hydroxylase deficiency. **Poster presentation** at the joint Lawson Wilkins & European Society for Pediatric Endocrinology Meeting, Montreal, Canada.
18. Charmandari E, Eisenhofer G, Keil M, Carlson A, New MI, Chrousos GP, Merke DP. (2001) Adrenomedullary function may predict phenotype and genotype in classic 21-hydroxylase deficiency. **Poster presentation** at the joint Lawson Wilkins & European Society for Pediatric Endocrinology Meeting, Montreal, Canada.
19. Charmandari E, Weise M, Bornstein SR, Eisenhofer G, Keil MF, Chrousos GP, Merke DP. (2001) Elevated serum leptin and insulin concentrations in patients with adrenomedullary hypofunction due to congenital adrenal hyperplasia. **Poster presentation** at the National Institutes of Health Research Festival, Bethesda, Maryland, USA.
20. Charmandari E, Chrousos GP, Kino T. (2001) Human glucocorticoid receptor (hGR) beta isoform suppresses both transcriptional activation functions AF-1 and AF-2 of hGR $\alpha$ . **Poster presentation** at the National Institutes of Health Research Festival, Bethesda, Maryland, USA.
21. Charmandari E, Weise M, Keil MF, Eisenhofer G, Bornstein SR, Chrousos GP, Merke DP. (2002) Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance. **Poster presentation** at the joint Pediatric Academy Societies and Lawson Wilkins Society for Pediatric Endocrinology Meeting, Baltimore, Maryland, USA.
22. Weise M, Mehlinger SL, Drinkard D, Charmandari E, Eisenhofer G, Chrousos GP, Merke DP. (2002) Children with congenital adrenal hyperplasia have normal short-term high-intensity exercise tolerance despite decreased adrenomedullary reserve. **Oral presentation** at the 84<sup>th</sup> Endocrine Society Annual Meeting, San Francisco, California, USA.
23. Charmandari E, Vottero A, Latronico AC, Mendonca B, Chrousos GP, Kino T. (2002) Differential interaction and activation function 2 of natural glucocorticoid receptor mutants causing familial glucocorticoid resistance. **Poster presentation** at the 84<sup>th</sup> Endocrine Society Annual Meeting, San Francisco, California, USA.
24. Charmandari E, Chrousos GP, Kino T. (2002) The human glucocorticoid receptor (GR)  $\beta$  isoform interacts with coactivators only through its transcriptional activation function (AF) 1 region, and suppresses both AF1 and AF2 activities of GR $\alpha$ . **Poster presentation** at the 84<sup>th</sup> Endocrine Society Annual Meeting, San Francisco, California, USA.
25. Roche EF, Charmandari E, Dattani M, Hindmarsh PC. (2002) Blood pressure in patients with congenital adrenal hyperplasia, 21-hydroxylase deficiency. **Poster presentation** at the 41<sup>st</sup> European Society for Pediatric Endocrinology Meeting, Madrid, Spain.

26. Charmandari E, Merke DP, Negro P, Keil MF, Gold PW, Chrousos GP. (2002) Endocrinologic and psychologic evaluation of 21-hydroxylase deficient carriers and normal subjects. **Poster presentation** at the 41<sup>st</sup> European Society for Pediatric Endocrinology Meeting, Madrid, Spain.
27. Charmandari E, Leong GM, Reynolds JC, Hill S, Chrousos GP, Nieman LK. (2003) Bone mineral density and body composition following cure of Cushing's disease in adolescence. **Poster presentation** at the 85<sup>th</sup> Endocrine Society Annual Meeting, Philadelphia, Pennsylvania, USA.
28. Charmandari E, Kino T, Vottero A, Chrousos GP. (2003) Natural glucocorticoid receptor mutants causing generalized glucocorticoid resistance: Molecular genotype, genetic transmission and clinical phenotype. **Poster Presentation** at the National Institutes of Health Research Festival, Bethesda, Maryland, USA.
29. Kino T, DeMartino M, Charmandari E, Outas T, Ichijo T, Pavlakis G, Chrousos GP. (2004) The human immunodeficiency virus type-1 (HIV-1) accessory protein Vpr inhibits the effect of insulin on members of the Foxo subfamily of forkhead proteins by interfering with its binding to 14-3-3 proteins: potential clinical implications on the insulin resistance of HIV-1-infected patients. **Oral presentation** at the 86<sup>th</sup> Endocrine Society Annual Meeting, New Orleans, Louisiana, USA.
30. Charmandari E, Kino T, Tiulpakov A, Zachman K, Raji A, Chrousos GP. (2004) A novel, carboxyl-terminal point mutation of the human glucocorticoid receptor gene causing glucocorticoid resistance: Decreased affinity for ligand, reduced transactivation, and dominant negative activity upon the wild-type receptor. **Oral presentation** at the 86<sup>th</sup> Endocrine Society Annual Meeting, New Orleans, Louisiana, USA.
31. Charmandari E, Merke DP, Negro PJ, Keil MF, Martinez P, Haim A, Gold PW, Chrousos GP. (2004) Carriers of 21-hydroxylase deficiency are mildly hypocortisolemic: Potential clinical implications. **Poster presentation** at the 86<sup>th</sup> Endocrine Society Annual Meeting, New Orleans, Louisiana, USA.
32. Charmandari E, Chrousos GP, Bhattacharyya N, Vottero A, Souvatzoglou E, Kino T. (2004) The human glucocorticoid receptor (hGR)  $\beta$  isoform suppresses the transcriptional activity of hGR $\alpha$  by interfering with binding of hGR $\alpha$  to coactivator molecules through its preserved activation function (AF)-1. **Poster presentation** at the 86<sup>th</sup> Endocrine Society Annual Meeting, New Orleans, Louisiana, USA.
33. Raji A, Charmandari E, Tiulpakov A, Kino T, Zachman K, Chrousos GP. (2004) A novel point mutation in the ligand-binding domain of the human glucocorticoid receptor gene causes glucocorticoid resistance. **Poster presentation** at the 86<sup>th</sup> Endocrine Society Annual Meeting, New Orleans, Louisiana, USA.
34. Charmandari E, Jubiz W, Kino T, Ichijo T, Mejia L, Zachman K, Chrousos GP. (2005) Two novel point mutations in the amino-terminal and ligand-binding domains of the human glucocorticoid receptor are associated with generalized glucocorticoid resistance in newly diagnosed patients. **Poster presentation** at the 39<sup>th</sup> Annual Meeting of the European Society for Clinical Investigation, Athens, Greece.
35. Charmandari E, Kino T, Ichijo T, Zachman K, Chrousos GP. (2005) Molecular characterization of the human glucocorticoid receptor (hGR) gene mutations hGR $\alpha$ R477H and hGR $\alpha$ G679S

causing generalized glucocorticoid resistance: Absence of dominant negative activity despite asymmetric binding to p160 coactivators. **Poster presentation** at the 87th Endocrine Society Annual Meeting, San Diego, California, USA.

36. Kino T, Liou SH, Charmandari E, Chrousos GP. (2005) Pathologic natural human glucocorticoid receptor (GR) mutants and the natural GR isoform  $\beta$  demonstrate reduced motility inside the nucleus of living cells. Suggestion of decreased dynamic interactions with DNA and chromatin, transcriptional intermediate and proteasomal proteins. **Oral presentation** at the 87<sup>th</sup> Endocrine Society Annual Meeting, San Diego, California, USA.
37. Kino T, Souvatzoglou E, Charmandari E, Driggers P, Mayers C, Alatsatianos A, Manoli I, Westphal H, Chrousos GP, Segars JH. (2005) Brx, a cytoplasmic Rho family guanine nucleotide exchange factor, functions as a molecular hub to couple glucocorticoid and membrane receptor-initiated signals. **Oral presentation** at the 87<sup>th</sup> Endocrine Society Annual Meeting, San Diego, California, USA.
38. Michel-Calemard L, Charmandari E, Achermann J, Scordis N, Morel Y. (2005) Large rearrangements of the HSD17B3 gene: A new type of mutation responsible for 17 $\beta$ -HSD deficiency. **Poster presentation** at the ESPE/LWPES 7th Joint Meeting, Lyon, France.
39. Charmandari E, Kino T, Ichijo T, Jubiz W, Zachman K, Mejia L, Chrousos GP. (2006) A novel point mutation in Helix 11 of the ligand-binding domain of the human glucocorticoid receptor gene causing generalized glucocorticoid resistance. **Poster presentation** at the 88<sup>th</sup> Endocrine Society Annual Meeting, Boston, Massachusetts, USA.
40. Charmandari E, Ichijo T, Jubiz W, Zachman K, Chrousos GP, Kino T. (2006) A novel point mutation in the amino terminal domain of the human glucocorticoid receptor gene enhances glucocorticoid-mediated gene expression. **Poster presentation** at the 88<sup>th</sup> Endocrine Society Annual Meeting, Boston, Massachusetts, USA.
41. Charmandari E, Kino T, Ichijo T, Zachman K, Chrousos GP. (2007) A novel, point mutation in Helix 11 of the ligand-binding domain of the human glucocorticoid receptor gene and molecular characterization of the mutant receptor hGR $\alpha$ F737L. **Poster presentation** at the Society for Endocrinology Meeting, March 5-8 2007, Birmingham, UK.
42. Charmandari E, Kino T, Ichijo T, Zachman K, Chrousos GP. (2007) Novel causes of generalized glucocorticoid insensitivity: Lessons from the crystal structure of the ligand-binding domain of the human glucocorticoid receptor. **Poster presentation** at the 89<sup>th</sup> Endocrine Society Annual Meeting, Toronto, Canada.
43. Charmandari E, Kino T, Ichijo T, Chrousos GP. (2007) Generalized glucocorticoid insensitivity: Clinical phenotype and molecular mechanisms. **Oral (Symposium) presentation** at the 46<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Helsinki, Finland (*Henning-Andersen Prize*).
44. Charmandari E, Kino T, Ichijo T, Zachman K, Chrousos GP. (2007) Novel causes of generalized glucocorticoid insensitivity: Lessons from the crystal structure of the ligand-binding domain of the human glucocorticoid receptor. **Oral (Symposium) presentation** at the 46<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Helsinki, Finland.

45. Arundel P, Alvi S, Barth J, Field H, Majumdar R, Butler G, Charmandari E. (2007) Adrenocorticotropin hypersecretion and pituitary microadenoma in a child with adrenal hypoplasia congenita. **Poster presentation** at the 46<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Helsinki, Finland.
46. Charmandari E, Ichijo T, Jubiz W, Zachman K, Chrousos GP, Kino T. (2007) Identification of a novel, point mutation in the amino terminal domain of the human glucocorticoid receptor (hGR) gene enhancing glucocorticoid-mediated gene expression and molecular characterization of the mutant receptor hGR $\alpha$ D401H. **Poster presentation** at the 46<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Helsinki, Finland.
47. Majumdar R, Feltbower R, Shapiro L, Arundel P, Charmandari E, Butler G, Alvi S. (2007) Incidence and aetiology of congenital hypothyroidism in Leeds, UK. **Poster presentation** at the 46<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Helsinki, Finland.
48. Charmandari E, Kino T, Komianou E, Sertedaki A, Kassiou K, Chrousos GP. (2008) A novel point mutation in the DNA-binding domain of the human glucocorticoid receptor gene causing generalized glucocorticoid resistance. **Poster presentation** at the 90<sup>th</sup> Endocrine Society Annual Meeting, San Francisco, California, USA.
49. Sertedaki A, Braatvedt G, Galata Z, Nicolaides NC, Chrousos GP, Charmandari E. (2009) A novel point mutation in the ligand-binding domain of the human glucocorticoid receptor gene causing Generalized Glucocorticoid Resistance. **Poster presentation** at the joint Lawson Wilkins & European Society for Pediatric Endocrinology Meeting, New York, USA.
50. Galata Z, Moschonis G, Makridakis M, Dimitraki P, Nicolaides NC, Chrousos GP, Manios Y, Vlahou A, Charmandari E. (2009) Obese children demonstrate alterations in the expression of lipoproteins and coagulation factors in plasma proteomic analysis. **Poster presentation** at the joint Lawson Wilkins & European Society for Pediatric Endocrinology Meeting, New York, USA.
51. Galata Z, Moschonis G, Makridakis M, Dimitraki P, Nicolaides NC, Chrousos GP, Manios Y, Vlahou A, Charmandari E. (2010) Plasma proteomic analysis in obese and overweight children. **Oral presentation** at the 49<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Prague, Czech Republic.
52. Galata Z, Moschonis G, Makridakis M, Dimitraki P, Nicolaides NC, Chrousos GP, Manios Y, Vlahou A, Charmandari E. (2010) Plasma proteomic analysis in obese and overweight children. **Oral presentation** at the joint 49<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Prague, Czech Republic.
53. Charmandari E. (2010) Adrenals - Yearbook of Pediatric Endocrinology. **Oral presentation** at the joint 49<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Prague, Czech Republic.
54. Charmandari E. (2011) Generalized glucocorticoid resistance and hypersensitivity states. **Oral presentation** at the 45<sup>th</sup> Annual Scientific Meeting of the European Society for Clinical Investigation, Heraklion, Crete, Greece.
55. Kino T, Charmandari E, Lambrou GI, Pavlaki A, Koide H, Ng SSM, Chrousos GP. (2011) Circadian CLOCK-mediated gene-specific regulation of peripheral glucocorticoid receptor

transcriptional activity by acetylation in man. **Oral presentation** at the 92<sup>nd</sup> Endocrine Society Annual Meeting, Boston, MA, USA.

56. Nicolaides NC, Geer E, Sertedaki A, Charmandari E. (2011) Novel mutation in glucocorticoid receptor gene causing Primary Generalized Glucocorticoid Resistance (Chrousos syndrome). **Poster presentation** at the joint 50<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Glasgow, United Kingdom.
57. Roberts ML, Kino T, Nicolaides NC, Katsantoni E, Sertedaki A, Charmandari E. (2011) Novel mechanisms of Primary Generalized Glucocorticoid Resistance or Chrousos Syndrome. **Poster presentation** at the joint 50<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Glasgow, United Kingdom.
58. Charmandari E. (2011) Primary Generalized Glucocorticoid Resistance and Hypersensitivity. **Poster presentation** at the joint 50<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Glasgow, United Kingdom.
59. Hindmarsh PC, Hill N, Dattani MT, Peters CJ, Charmandari E, Matthews DR. (2011) Deconvolution analysis of 24h serum cortisol profiles informs the amount and distribution of Hydrocortisone replacement therapy. **Poster presentation** at the joint 50<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Glasgow, United Kingdom.
60. Charmandari E. (2011) Adrenals - Yearbook of Pediatric Endocrinology. **Oral presentation** at the joint 50<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Glasgow, United Kingdom.
61. Hindmarsh PC, Hill N, Dattani MT, Peters CJ, Charmandari E, Matthews DR. (2011) Deconvolution analysis of 24h serum cortisol profiles informs the amount and distribution of Hydrocortisone replacement therapy. **Oral presentation** at the 30<sup>th</sup> Meeting of the British Society for Paediatric Endocrinology and Diabetes, London, UK.
62. Davies P, Borkenstein M, Charmandari E, Kim HS, Kirk J, Kostalova L, Lebl J, Loche S, Luczay A, Nicolino M, Norgren S, Rodriguez Arnao D, VanderMeulen J, Gasteyger C, Zieschang J, Zignani M; on behalf of the ECOS investigator group. (2012) Quantifying Adherence to Growth Hormone Treatment: The Easypod<sup>TM</sup> Connect Observational Study (ECOS) **Poster presentation** at the 93<sup>rd</sup> Endocrine Society Annual Meeting, Houston, TX, USA.
63. Charmandari E, Sertedaki A, Kino T, Merakou C, Hoffman D, Hutch MM, Hurt D, Lin L, Xekoiki P, Stratakis C, Chrousos GP. (2012) A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early onset autosomal dominant hypertension. **Oral presentation** at the joint 51<sup>st</sup> European Society for Pediatric Endocrinology Meeting, Leipzig, Germany.
64. Nicolaides NC, Roberts ML, Kino T, Katsantoni E, Sertedaki A, Chrousos GP, Charmandari E. (2012) The Role of S-Palmitoylation of human glucocorticoid receptor in mediating the non-genomic actions of glucocorticoids. **Poster presentation** at the joint 51<sup>st</sup> European Society for Pediatric Endocrinology Meeting, Leipzig, Germany.
65. Roberts ML, Nicolaides NC, Kino T, Katsantoni E, Sertedaki A, Chrousos GP, Charmandari E. (2012) Functional characterization of a novel mutation in the human glucocorticoid receptor

gene causing Primary Generalized Glucocorticoid Resistance. **Oral presentation** at the joint 51<sup>st</sup> European Society for Pediatric Endocrinology Meeting, Leipzig, Germany.

66. Farakla I, Kouli E, Arditi J, Moutsatsou P, Drakopoulou M, Papassotiriou I, Chrousos GP, Charmandari E. (2012) Comparative effects of oral honey versus glucose tolerance test solutions on circulating glucose and insulin concentrations in obese prepubertal girls. **Poster presentation** at the joint 51<sup>st</sup> European Society for Pediatric Endocrinology Meeting, Leipzig, Germany.
67. Charmandari E. Katsantoni E, Triantafyllou P, Christophoridis A, Katzos G, Kino T, Nicolaides NC, Sertedaki A, Chrousos GP. (2012) Transient Generalized Glucocorticoid Hypersensitivity: Clinical manifestations and transcriptomics profile. **Poster presentation** at the joint 51<sup>st</sup> European Society for Pediatric Endocrinology Meeting, Leipzig, Germany.
68. Nicolaides NC, Sertedaki A, Chrousos GP, Charmandari E. (2012) Molecular mechanisms of action of a novel point mutation of the human glucocorticoid receptor gene causing Primary Generalized Glucocorticoid Resistance. **Poster presentation** at the joint 51<sup>st</sup> European Society for Pediatric Endocrinology Meeting, Leipzig, Germany.
69. Charmandari E. (2012) 2012 Working Party on 'Disorders of Sex Development' (DSD): Evaluation report. **Oral presentation** at the joint 51<sup>st</sup> European Society for Pediatric Endocrinology Meeting, Leipzig, Germany.
70. Charmandari E. (2012) Adrenals - Yearbook of Pediatric Endocrinology. **Oral presentation** at the joint 51<sup>st</sup> European Society for Pediatric Endocrinology Meeting, Leipzig, Germany.
71. Hurt DE, Mayama T, Charmandari E. Kino T. (2013) Structural analysis on the ligand-binding domain of the known pathologic glucocorticoid receptors reveals structure-function link in its ligand-binding pocket and activation function (AF)-2. **Poster presentation** at the 94<sup>th</sup> Endocrine Society Annual Meeting, San Francisco, CA, USA.
72. Charmandari E. (2013) Adrenals - Yearbook of Pediatric Endocrinology. **Oral presentation** at the 9<sup>th</sup> Joint Meeting of Paediatric Endocrinology, Milan, Italy (September 19 - 22, 2013).
73. Charmandari E. Zhang M, Gontijo Silveira L, Chrousos GP, Sertedaki A, Latronico AC, Segaloff DL. (2013) A case of Leydig cell hypoplasia associated with two distinct homozygous mutations of the human Luteinizing Hormone/Chorionic Gonadotropin receptor that include a novel mutation with unusual functional properties. **Oral presentation** at the 9<sup>th</sup> Joint Meeting of Paediatric Endocrinology, Milan, Italy (September 19 - 22, 2013).
74. Nicolaides NC, Geer E, Sertedaki A, Chrousos GP, Charmandari E. (2013) A novel point mutation in the ligand-binding domain of the human glucocorticoid receptor (hGR) gene causing Primary Generalized Glucocorticoid Resistance. **Oral presentation** at the 9<sup>th</sup> Joint Meeting of Paediatric Endocrinology, Milan, Italy (September 19 - 22, 2013).
75. Davies PSW, Kirk J, Lebl J, Luczay A, VanderMeulen J, Loche S, Norgren S, Kostalova L, Kim HS, Nicolino M, Charmandari E. Zieschang J, Stoyanov G. (2013) The easypod<sup>TM</sup> connect observational study (ECOS): adherence to recombinant human growth hormone (rhGH) therapy in younger and older children. **Poster presentation** at the 9<sup>th</sup> Joint Meeting of Paediatric Endocrinology, Milan, Italy (September 19 - 22, 2013).

76. Nicolaides NC, Sertedaki A, Chrousos GP, Charmandari E. (2013) Molecular mechanisms of action of the natural human glucocorticoid receptor (hGR) mutant hGR $\alpha$ T556I causing Primary Generalized Glucocorticoid Resistance. **Poster presentation** at the 9<sup>th</sup> Joint Meeting of Paediatric Endocrinology, Milan, Italy (September 19 - 22, 2013).
77. Sertedaki A, Nicolaides NC, Chrousos GP, Charmandari E. (2013) A novel mutation of the human glucocorticoid receptor (hGR) gene causing mild Primary Generalized Glucocorticoid Resistance. **Poster presentation** at the 9<sup>th</sup> Joint Meeting of Paediatric Endocrinology, Milan, Italy (September 19 - 22, 2013).
78. Sertedaki A, Markou A, Piaditis G, Chrousos GP, Charmandari E. (2013) Mutations of the KCNJ5 gene in patients with hypertension and increased aldosterone response to ACTH. **Poster presentation** at the 9<sup>th</sup> Joint Meeting of Paediatric Endocrinology, Milan, Italy (September 19 - 22, 2013).
79. Nicolaides NC, Geer EB, Vlachakis D, Sertedaki A, Bacopoulou I, Kossida S, Chrousos GP, Charmandari E. (2014) A novel point mutation of the human glucocorticoid receptor gene causes Primary Generalized Glucocorticoid Resistance through reduced flexibility of helix 10 of the ligand-binding domain of the receptor and decreased affinity for the ligand. **Poster presentation** at the 95<sup>th</sup> Endocrine Society Annual Meeting, Chicago, IL, USA.
80. Sertedaki A, Markou A, Kaltsas G, Androulakis I, Pappa T, Gouli A, Papanastasiou L, Zacharoulis A, Karavidas A, Ragkou D, Vlachakis D, Kossida S, Campanac E, Hoffman DA, De La Luz M, Xekouki P, Stratakis CA, Charmandari E. Chrousos GP, Piaditis GP. (2014) Mutations of the KCNJ5 gene in patients with hypertension and increased aldosterone response to ACTH. **Power-point Preview presentation** at the 95<sup>th</sup> Endocrine Society Annual Meeting, Chicago, IL, USA.
81. Charmandari E. (2014) Congenital Adrenal Hyperplasia. **Oral (Symposium) presentation** at the 53<sup>rd</sup> European Society for Pediatric Endocrinology Meeting, Dublin, Ireland (September 18-20, 2014).
82. Charmandari E. (2014) Adrenals - Yearbook of Pediatric Endocrinology. **Oral presentation** at the 53<sup>rd</sup> European Society for Pediatric Endocrinology Meeting, Dublin, Ireland (September 18-20, 2014).
83. Nicolaides NC, Lamprokostopoulou A, Polyzos A, Kino T, Katsantoni E, Triantafyllou P, Christophoridis A, Katzos G, Drakopoulou M, Sertedaki A, Chrousos GP, Charmandari E. (2014) Transient Generalized Glucocorticoid Hypersensitivity: Clinical manifestations, endocrinologic evaluation and transcriptomic profile: The potential role of NF- $\kappa$ B. **Poster presentation** at the 53<sup>rd</sup> European Society for Pediatric Endocrinology Meeting, Dublin, Ireland (September 18-20, 2014).
84. Nicolaides NC, Vlachakis D, Sertedaki A, Kossida S, Chrousos GP, Charmandari E. (2014) Functional characterization of a novel heterozygous point mutation in the human glucocorticoid receptor gene causing Primary Generalized Glucocorticoid Resistance. **Poster presentation** at the 53<sup>rd</sup> European Society for Pediatric Endocrinology Meeting, Dublin, Ireland (September 18-20, 2014).
85. Nicolaides NC, Roberts ML, Kino T, Katsantoni E, Sertedaki A, Chrousos GP, Charmandari E. (2014) Molecular mechanisms of nongenomic glucocorticoid actions: The role of human

glucocorticoid receptor S-Palmitoylation. **Oral presentation** at the 53<sup>rd</sup> European Society for Pediatric Endocrinology Meeting, Dublin, Ireland (September 18-20, 2014).

86. Farakla I, Papadopoulos GE, Kouli E, Arditi J, Moutsatsou P, Drakopoulou M, Papasotiriou I, Chrousos GP, Charmandari E. (2014) The effect of honey on plasma glucose and insulin concentrations in obese prepubertal girls. **Poster presentation** at the 53<sup>rd</sup> European Society for Pediatric Endocrinology Meeting, Dublin, Ireland (September 18-20, 2014).
87. Fragouli T, Sertedaki A, Farakla I, Nicolaides NC, Drakopoulou M, Papasotiriou I, Chrousos GP, Charmandari E. (2014) Expression levels of the Growth-arrest-specific transcript 5 (Gas5) in overweight and obese children and adolescents. **Poster presentation** at the 53<sup>rd</sup> European Society for Pediatric Endocrinology Meeting, Dublin, Ireland (September 18-20, 2014).
88. Lamprokostopoulou A, Moschonis G, Manios I, Chrousos GP, Charmandari E. (2014) Obesity in childhood and adolescence is associated with decreased leucocyte telomere length. **Oral presentation** at the 53<sup>rd</sup> European Society for Pediatric Endocrinology Meeting, Dublin, Ireland (September 18-20, 2014).
89. Giannios C, Farakla I, Papadopoulos G, Bakopoulou I, Nicolaides NC, Papathanasiou C, Drakopoulou M, Chrousos GP, Charmandari E. (2014) The prevalence of 25-hydroxyvitamin D insufficiency and deficiency among overweight and obese children and adolescents in Greece. **Power-point Oral presentation** at the 53<sup>rd</sup> European Society for Pediatric Endocrinology Meeting, Dublin, Ireland (September 18-20, 2014).
90. Davies P, Luczay A, Charmandari E., Kirk J, Kim HS, Kostalova L, Nicolino M, Borkenstein M, Rodriguez Arnao MD, Calzada-León R, Norgren S, VanderMeulen J, Loche S, Belgorosky A, Du M, Stoyanov G, Koledova E, Zhao, Lebl J. (2015) The Easypod™ Connect Observational Study (ECOS): results from the 2014 interim analysis. **Poster presentation** at the 96<sup>th</sup> Endocrine Society Annual Meeting, San Diego, CA, USA.
91. Kassari P, Papaioannou P, Charmandari E. (2015) A Systemic Approach for the Management of the Program entitled ‘Development of a National System for the Prevention and Management of Overweight and Obesity in Childhood and Adolescence in Greece’. **E-Poster presentation** at the 54<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Barcelona, Spain (October 1-3, 2015).
92. Nicolaides NC, Skyrila E, Vlachakis D, Psarra AMG, Sertedaki A, Kossida S, Charmandari E. (2015) The Natural Mutant Receptor hGR $\alpha$ T556I Causes Primary Generalized Glucocorticoid Resistance Through Decreased Affinity for the Ligand and Impaired Interaction with the GRIP1 Coactivator. **E-Poster presentation** at the 54<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Barcelona, Spain (October 1-3, 2015).
93. Papadopoulos G, Farakla I, Bakopoulou S, Giannios C, Kouli E, Georgiou A, Romas S, Terzioglou E, Koniari E, Papathanasiou C, Kassari P, Nicolaides N, Critselis E, Manios Y, Charmandari E. (2015) The Effectiveness of a Comprehensive and Personalized Plan of Action in the Prevention and Management of Overweight and Obesity in Childhood and Adolescence. **E-Poster presentation** at the 54<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Barcelona, Spain (October 1-3, 2015).
94. Koltsida G, Farakla I, Papanikolaou A, Kolaitis G, Mantzou E, Charmandari E. (2015) Carriers of 21- Hydroxylase Deficiency Demonstrate Increased Psychological Vulnerability to Stress.



**Mini-Poster (Oral) and E-Poster presentation** at the 54<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Barcelona, Spain (October 1-3, 2015).

95. Giannios C, Farakla I, Papadopoulos G, Koniari E, Papathanasiou C, Kassari P, Charmandari E. (2015) Increased prevalence of 25-hydroxyvitamin D insufficiency and deficiency among overweight and obese children and adolescents in Greece. **E-Poster presentation** at the 54<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Barcelona, Spain (October 1-3, 2015).
96. Charmandari E. (2015) Adrenals - Yearbook of Pediatric Endocrinology. **Oral presentation** at the 54<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Barcelona, Spain (October 1-3, 2015).
97. Charmandari E., Hindmarsh PC (2015) Discordance between the cortisol dose for replacement and that required for suppression of Androstenedione (A4) and 17-hydroxyprogesterone (17-OHP) in Congenital Adrenal Hyperplasia. **E-Poster presentation** at the 43<sup>rd</sup> Annual Meeting of the British Society for Paediatric Endocrinology and Diabetes, Sheffield, UK (November 25-27, 2015).
98. Charmandari E., Hindmarsh PC (2015) Variation in absorption and half-life of Hydrocortisone: A need to consider plasma terminal half-life in dosing schedules. **E-Poster presentation** at the 43<sup>rd</sup> Annual Meeting of the British Society for Paediatric Endocrinology and Diabetes, Sheffield, UK (November 25-27, 2015).
99. Charmandari E. (2016) Adrenals - Yearbook of Pediatric Endocrinology. **Oral presentation** at the 55<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Paris, France (September 10 – 12, 2016).
100. Georgiou A, Karampatsou S, Genitsaridi S, Nikolaou M, Farakla I, Papadopoulos G, Giannios C, Papageorgiou I, Boleti O, Kouli E, Tsoutsouloupoulou K, Manios Y, Charmandari E. (2016) Dietary habits of children and adolescents attending an Out-patient Clinic for the Prevention and Management of Overweight and Obesity in Greece. **E-Poster presentation** at the 55<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Paris, France (September 10 – 12, 2016).
101. Genitsaridi S, Karampatsou S, Papageorgiou I, Papadopoulos G, Farakla I, Kouli E, Georgiou A, Romas S, Terzioglou E, Papathanasiou C, Kassari P, Giannios C, Nicolaides NC, Manios Y, Charmandari E. (2016) A comprehensive and multidisciplinary management plan is extremely effective at reducing the prevalence of overweight and obesity in childhood and adolescence. **E-Poster presentation** at the 55<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Paris, France (September 10 – 12, 2016).
102. Stefa A, Lamprokostopoulou A, Kontogeorgou A, Briana D, Malamitsi-Puchner A, Tsitsilonis O, Gagos S, Charmandari E. (2016) The effect of intrauterine stress on leukocyte telomere length in newborns. **E-Poster presentation** at the 55<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Paris, France (September 10 – 12, 2016).
103. Stavrou S, Nicolaides NC, Papageorgiou I, Papadopoulou P, Terzioglou E, Darviri C, Chrousos GP, Charmandari E. (2016) The effectiveness of a stress management intervention program in the management of overweight and obesity in childhood and adolescence. **E-Poster presentation** at the 55<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Paris, France (September 10 – 12, 2016).

104. Nicolaides NC, Polyzos A, Koniari E, Lamprokostopoulou A, Golfinopoulou E, Papathanasiou C, Sertedaki A, Thanos D, Charmandari E. (2016) Transcriptomic analysis in healthy subjects with differences in tissue sensitivity to glucocorticoids identifies novel disease-associated genes. **Oral presentation** at the 55<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Paris, France (September 10 – 12, 2016).
105. Lamprokostopoulou A, Varela A, Katsimpoulas M, Dimitriou C, Athanasiadis N, Soultou E, Stefa A, Mavroides M, Davos CH, Chrousos GP, Kino T, Georgopoulos S, Charmandari E. (2016) Impaired cardiac function in a mouse model of Generalized Glucocorticoid Resistance. **Oral presentation** at the 55<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Paris, France (September 10 – 12, 2016).
106. Kassari P, Papaioannou P, Billiris A, Karanikas H, Eleftheriou S, Thireos E, Manios Y, Chrousos GP, Charmandari E. (2016) e-Health: A National Registry and Therapeutic Algorithm for the Prevention and Management of Overweight and Obesity in Childhood and Adolescence in Greece. **E-Poster presentation** at the 55<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Paris, France (September 10 – 12, 2016).
107. Bacopoulou F, Kolias E, Aravantinos L, Mantzou A, Doulgeraki A, Spanoudi F, Deligeoroglou E, Charmandari E. (2016) Randomized controlled study comparing vitamin D and omega 3-fatty acids supplementation in adolescents with polycystic ovary syndrome. **E-Poster presentation** at the 55<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Paris, France (September 10 – 12, 2016).
108. Vlachakis D, Nicolaides NC, Papageorgiou L, Lamprokostopoulou A, Charmandari E. (2016) Tracing the Glucocorticoid Receptor evolutionary pedigree: insights from a comprehensive phylogenetic analysis of the full NR super-family. **Oral presentation** at the 55<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Paris, France (September 10 – 12, 2016).
109. Kyritsi EM, Nicolaides NC, Lamprokostopoulou A, Xaidara A, Georgiadou E, Dimitropoulou V, Stefa A, Sertedaki A, Chrousos GP, Charmandari E. (2016) Transient Generalized Glucocorticoid Hypersensitivity Syndrome. **E-Poster presentation** at the 55<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Paris, France (September 10 – 12, 2016).
110. Sertedaki A, Polyzos A, Nicolaides NC, Thanos D, Charmandari E. (2016) Transient Generalized Glucocorticoid Hypersensitivity Syndrome. **E-Poster presentation** at the 55<sup>th</sup> European Society for Pediatric Endocrinology Meeting, Paris, France (September 10 – 12, 2016).
111. Vardas K, Ilia S, Sertedaki A, Charmandari E., Stratakis CA, Briassouli E, Goukos D, Psarra K, Botoula E, Tsagarakis S, Mageira E, Routsis C, Nanas S, Briassoulis G. Glucocorticoid receptor expression is higher in patients with sepsis and non-survivors, and is related to cortisol heat-shock proteins and cytokines. **Poster Presentation** at the 29th Annual Congress European Society of Intensive Care Medicine, Milan, Italy (October 1-5, 2016).
112. Charmandari E., Michalakos S, Sakellariou D, Koledova E, Chrousos G. (2018) Adherence and long-term outcomes of therapy in pediatric subjects in Greece using easypod™ electromechanical device for growth hormone treatment: the Phase IV multicenter Easypod™

Connect Observational Study (ECOS). **Poster presentation** at the 57th European Society for Pediatric Endocrinology Meeting, Athens, Greece (September 27 – 29, 2018).

113. Nicolaides NC, Ioannidi MK, Koniari E, Sertedaki A, Klapa MI, Chrousos GP, Charmandari E. (2018) Untargeted plasma metabolomics in subjects with differences in tissue glucocorticoid sensitivity identifies a novel metabolic signature. **Oral presentation** at the 57th European Society for Pediatric Endocrinology Meeting, Athens, Greece (September 27 – 29, 2018).
114. Nicolaides NC, Kyritsi EM, Foutadakis S, Vatselas G, Lamprokostopoulou A, Stefa A, Sertedaki A, Thanos D, Chrousos GP, Charmandari E. (2018) Generalized Glucocorticoid Hypersensitivity Syndrome: From clinical manifestations and endocrinologic evaluation to transcriptomic analysis. **Poster presentation** at the 57th European Society for Pediatric Endocrinology Meeting, Athens, Greece (September 27 – 29, 2018).
115. Genitsaridi S, Karampatsou S, Papageorgiou I, Mantzou A, Paltoglou G, Kourkouti C, Papathanasiou C, Kassari P, Nicolaides NC, Charmandari E. (2018) Hair cortisol concentrations in overweight and obese children and adolescents. **Poster presentation** at the 57th European Society for Pediatric Endocrinology Meeting, Athens, Greece (September 27 – 29, 2018).
116. Sertedaki A, Marinakis N, Nicolaides NC, Chrousos G, Charmandari E. (2018) Whole Exome Sequencing in patients with Primary Generalized Glucocorticoid Resistance identifies a novel TRIM28 gene mutation (p.R230X). **Oral presentation** at the 57th European Society for Pediatric Endocrinology Meeting, Athens, Greece (September 27 – 29, 2018).
117. Karampatsou SI, Genitsaridi SM, Papageorgiou I, Charmandari E. (2018) The role of fibroblast-growth factor 21 and irisin in the pathogenesis of obesity in childhood and adolescence. **Poster presentation** at the 57th European Society for Pediatric Endocrinology Meeting, Athens, Greece (September 27 – 29, 2018).
118. Vasilakis IA, Kazakou P, Kogia C, Karaflou M, Chrousos GP, Charmandari E. (2018) A rare case of ACTH- independent Cushing's syndrome due to bilateral micronodular adrenal hyperplasia and myoclonic dystonia. **Poster presentation** at the 57th European Society for Pediatric Endocrinology Meeting, Athens, Greece (September 27 – 29, 2018).
119. Diou C, Ioakeimidis I, Charmandari E., Kassari P, Lekka I, Mars M, Bergh C, Doyle G, O' Malley G, Heimeier R, Lindroos AK, Sotiriou S, Koukoula E, Guillen S, Lymperopoulos G, Maglaveras N, Delopoulos A. (2018) Big data against childhood obesity. **Poster presentation** at the 57th European Society for Pediatric Endocrinology Meeting, Athens, Greece (September 27 – 29, 2018).
120. Giannios C, Nicolaides NC, Farakla I, Papadopoulos G, Gennitsaridi S, Karampatsou S, Kolaitis G, Chrousos GP, Charmandari E. (2018) The effect of vitamin D supplementation on metabolic syndrome parameters in overweight and obese children and adolescents in Greece. **Poster presentation** at the 57th European Society for Pediatric Endocrinology Meeting, Athens, Greece (September 27 – 29, 2018).
121. Papageorgiou L, Papakonstantinou E, Constantinos S, Raftopoulou S, Mitsis T, Nicolaides NC, Eliopoulos E, Charmandari E., Chrousos GP, Vlachakis D. (2018) An updated evolutionary study in Glucocorticoid receptors; insights from a comprehensive phylogenetic, SNP's and mutation's analysis of the Nuclear receptors family. **Poster presentation** at the 57th European Society for Pediatric Endocrinology Meeting, Athens, Greece (September 27 – 29, 2018).

122. Panagiotopoulou K, Koliopoulou V, Pergantou H, Dettoraki A, Michalopoulou A, Politi D, Stamati I, Charmandari E, Platokouki H. (2019) Quality of life of children with hemophilia in Greece. **Poster presentation** at the 12th Annual Congress of the European Association of Hemophilia and Allied Disorders (EAHAD), Prague, Czech Republic (February 6 – 8, 2019).
123. Maramis C, Ioakeimidis I, Kilintziz V, Stefanopoulos L, Lekka E, Papapanagiotou V, Diou C, Delopoulos A, Kassari P, Charmandari E, Manglaveras N. Developing a novel citizen scientist smartphone app for collecting behavioral and affective data from children populations. **Oral presentation** at the IEEE-EMBS International Conference on Biomedical and Health Informatics, Chicago, Illinois, USA (May 19-22, 2019).
124. Fylaktou E, Sertedaki A, Charmandari E. (2019) Molecular analysis of CYP21A2 gene in 100 patients with Congenital Adrenal Hyperplasia (CAH) due to 21-hydroxylase deficiency. **Poster presentation** at the European Human Genetics Conference, Gothenburg, Sweden (June 15 – 18, 2019).
125. Tragomalou A, Kassari P, Ioakeimidis I, Filis, K, Theodoropoulou E, Limberopoulos G, Perez Cuevas I, Karavidopoulou G, Diou C, Maramis C, Lekka E, Maglaveras N, Delopoulos A, Charmandari E. BigO: Bid Data against Childhood Obesity – A clinical pilot study. **Oral presentation** at the 1st International Congress of Childhood Welfare, Athens, Greece (July 5-6, 2019).
126. Kassari P, Billiris A, Karanikas H, Thireos E, Drakoulis N, Manios Y, Charmandari E. PEDOBESITY: A novel electronic application for the personalized management of overweight and obesity in childhood and adolescence. **Oral presentation** at the 1st International Congress of Childhood Welfare, Athens, Greece (July 5-6, 2019).
127. Tragomalou A, Kosti E, Sveroni K, Loukopoulou S, Binou M, Kourlaba G, Papadopoulou M, Kassari, Charmandari E. (2019) Assessment of cardiac function in obese children and adolescents with metabolic syndrome. **Poster presentation** at the 58th European Society for Pediatric Endocrinology Meeting, Vienna, Austria (September 19 – 21, 2019).
128. Kassari P, Tragomalou A, Ioakeimidis I, Filis K, Theodoropoulou E, Lymperopoulos G, Perez Cuevas I, Karavidopoulou Y, Diou C, Maramis C, Lekka E, Maglaveras N, Delopoulos A, Charmandari E. (2019) BigO: The use of new technologies for the management of childhood obesity – A clinical pilot study. **Poster presentation** at the 58th European Society for Pediatric Endocrinology Meeting, Vienna, Austria (September 19 – 21, 2019).
129. Kassari P, Billiris A, Karanikas H, Thireos E, Drakoulis N, Manios I, Charmandari E. (2019) PEDOBESITY: Development of intelligent multi-level information systems and specialized artificial intelligence algorithms for personalized management of obesity in childhood and adolescence. **Poster presentation** at the 58th European Society for Pediatric Endocrinology Meeting, Vienna, Austria (September 19 – 21, 2019).
130. Kassari P, Billiris A, Karanikas H, Thireos E, Drakoulis N, Manios I, Charmandari E. (2019) PEDOBESITY: Development of a novel electronic platform for personalized management of obesity in childhood and adolescence. **Oral presentation** at the 29th European Childhood Group Meeting, Katowice, Poland (November 16 – 20, 2019).

## B/ PUBLICATIONS IN NATIONAL CONFERENCE PROCEEDINGS

131. Androutsos O, Moschonis G, Drakopoulou M, Tanagra S, Siatista PE, Charmandari E, Pervanidou P, Kanaka-Gantenbein C, Manios Y, Chrousos GP. (2010) Risk factors for metabolic syndrome and hypovitaminosis D in primary school students. **Poster presentation** at the Annual Meeting of the Society for Atherosclerosis, Ioannina, Greece.
132. Moschonis G, Androutsos O, Drakopoulou M, Tanagra S, Koumbitski A, Charmandari E, Pervanidou P, Kanaka-Gantenbein C, Manios Y, Chrousos GP. (2010) High risk for hypovitaminosis D in primary school students with increased total and visceral fat mass. Health growth study. **Poster presentation** at the Annual Meeting of the Society for Atherosclerosis, Ioannina, Greece.
133. Papadopoulou N, Maria-Christina Zennaro, Kanaka-Gantenbein C, Chrousos GP, Charmandari E. (2011) A *de novo* mutation of the mineralocorticoid receptor gene causing Pseudohypoaldosteronism type I. **Poster presentation** at the Annual Meeting of the Hellenic Endocrine Society, Greece.
134. Nicolaides NC, Roberts ML, Kino T, Hurt DE, Katsantoni E, Sertedaki A, Chrousos GP, Charmandari E. (2013) A novel point mutation in the DNA-binding domain of the human glucocorticoid receptor gene causing Primary Generalized Glucocorticoid Resistance (Chrousos syndrome). **Oral presentation** at the 40<sup>th</sup> Hellenic Endocrine Society Meeting, Athens, Greece.
135. Nicolaides NC, Roberts ML, Kino T, Braadvedt G, Katsantoni E, Sertedaki A, Chrousos GP, Charmandari E. (2013) Identification and functional characterization of a novel point mutation of the human glucocorticoid receptor gene causing Primary Generalized Glucocorticoid Resistance (Chrousos syndrome). **Oral presentation** at the 40<sup>th</sup> Hellenic Endocrine Society Meeting, Athens, Greece.
136. Sertedaki A, Markou A, Piaditis G, Chrousos GP, Charmandari E. (2013) Mutations in the KCNJ5 gene in patients with idiopathic hypertension and hyperresponsiveness of aldosterone to ACTH. **Oral presentation** at the 40<sup>th</sup> Hellenic Endocrine Society Meeting, Athens, Greece.
137. Farakla I, Kouli E, Arditi J, Moutsatsou P, Drakopoulou M, Papassotiriou I, Chrousos GP, Charmandari E. (2013) The effect of honey on the concentrations of glucose and insulin in obese prepubertal girls. **Oral presentation** at the 40<sup>th</sup> Hellenic Endocrine Society Meeting, Athens, Greece.
138. Nicolaides NC, Sertedaki A, Chrousos GP, Charmandari E. (2013) Molecular mechanisms through which a novel point mutation of the human glucocorticoid receptor gene causes Primary Generalized Glucocorticoid Resistance. **Poster presentation** at the 40<sup>th</sup> Hellenic Endocrine Society Meeting, Athens, Greece.
139. Nicolaides NC, Roberts ML, Kino T, Katsantoni E, Sertedaki A, Chrousos GP, Charmandari E. (2013) The role of S-palmitoylation of the human glucocorticoid receptor in mediating the non-genomic actions of glucocorticoids. **Poster presentation** at the 40<sup>th</sup> Hellenic Endocrine Society Meeting, Athens, Greece.
140. Nicolaides NC, Katsantoni E, Triantafyllou P, Christoforidis A, Katzos G, Kino T, Sertedaki A, Chrousos GP, Charmandari E. (2013) Transient Generalized Glucocorticoid

Hypersensitivity: Clinical manifestations and transcriptomics profile. **Poster presentation** at the 40<sup>th</sup> Hellenic Endocrine Society Meeting, Athens, Greece.

141. Charmandari E. (2014) Development of a national system for the prevention and management of overweight and obesity. **Oral presentation** at the 7<sup>th</sup> State of the Art Adolescent Medicine Meeting, Athens, Greece (April 4-5, 2014).
142. Penio Kassari, Charmandari E. (2014) [www.childhood-obesity.gr](http://www.childhood-obesity.gr) - information on the prevention and management of overweight and obesity. **Oral presentation** at the 7<sup>th</sup> State of the Art Adolescent Medicine Meeting, Athens, Greece (April 4-5, 2014).
143. Nicolaides NC, Roberts ML, Kino T, Katsantoni E, Sertedaki A, Chrousos GP, Charmandari E. (2014) Molecular mechanisms of non genomic glucocorticoid actions: The role of S-palmitoylation of human glucocorticoid receptor. **Poster presentation** at the 41<sup>st</sup> Hellenic Endocrine Society Meeting, Porto Cheli, Greece (May 14-17, 2014).
144. Nicolaides NC, Lamprokosopoulou A, Polyzos A, Kino T, Katsantoni E, Triantafyllou P, Christoforidis A, Katzos G, Sertedaki A, Chrousos GP, Charmandari E. (2014) Clinical presentation and transcriptomic profile of a rare case of Transient Generalized Glucocorticoid Hypersensitivity. **Oral presentation** at the 41<sup>st</sup> Hellenic Endocrine Society Meeting, Porto Cheli, Greece (May 14-17, 2014).
145. Nicolaides NC, Sertedaki A, Chrousos GP, Charmandari E. (2014) A novel point mutation of the human glucocorticoid receptor gene causes Primary Generalized Glucocorticoid Resistance (Chrousos syndrome) through multiple molecular mechanisms. **Poster presentation** at the 41<sup>st</sup> Hellenic Endocrine Society Meeting, Porto Cheli, Greece (May 14-17, 2014).
146. Nicolaides NC, Vlachakis D, Sertedaki A, Kossida S, Chrousos GP, Charmandari E. (2014) A novel point mutation of the human glucocorticoid receptor gene causes Primary Generalized Glucocorticoid Resistance (Chrousos syndrome) through reduced flexibility of Helix 10 of the ligand-binding domain. **Oral presentation** at the 41<sup>st</sup> Hellenic Endocrine Society Meeting, Porto Cheli, Greece (May 14-17, 2014).
147. Farakla I, Kouli E, Arditi J, Moutsatsou P, Drakopoulou M, Papassotiriou I, Chrousos GP, Charmandari E. (2014) The effect of honey on the concentrations of glucose and insulin in obese prepubertal girls. **Oral presentation** at the 41<sup>st</sup> Hellenic Endocrine Society Meeting, Porto Cheli, Greece (May 14-17, 2014).
148. Lamprokostopoulou A, Moschonis G, Manios I, Chrousos GP, Charmandari E. (2014) Obesity in childhood and adolescence is associated with shorter leukocyte telomere length. **Oral presentation** at the 41<sup>st</sup> Hellenic Endocrine Society Meeting, Porto Cheli, Greece (May 14-17, 2014).
149. Penio Kassari, Charmandari E. (2015) Development of a national system for the prevention and management of overweight and obesity in Greece. **Oral presentation** at the 8<sup>th</sup> State of the Art Adolescent Medicine Meeting, Athens, Greece (March 13-14, 2015).
150. Nicolaides NC, Skyrila E, Vlachakis D, Sertedaki A, Kossida S, Chrousos GP, Charmandari E. (2015) The mutant human glucocorticoid receptor hGR $\alpha$ T556I causes Primary Generalized Glucocorticoid Resistance (Chrousos syndrome) through reduced binding to glucocorticoids and

delayed nuclear translocation. **Oral presentation** at the 42<sup>nd</sup> Hellenic Endocrine Society Meeting, Thessaloniki, Greece (May 6-10, 2015).

151. Kassari P, Charmandari E. (2016) National Registry for the prevention and management of overweight and obesity. **Oral presentation** at the 9th State of the Art Adolescent Medicine Meeting, Athens, Greece (April 1-2, 2016).
152. Stefa A, Lamprokostopoulou A, Kontogiorgou A, Briana D, Gagos S, Malamitsi-Puchner A, Charmandari E. (2016) The effect of endometrial stress on leukocyte telomere length. **Oral presentation** at the 43rd Hellenic Endocrine Society Meeting, Athens, Greece (April 20-23, 2016).
153. Kassari P, Papaioannou P, Billiris A, Karanikas X, Eleftheriou S, Thireos E, Manios Y, Chrousos GP, Charmandari E. (2017) e-Health: Development of an electronic database for the prevention and management of overweight and obesity in childhood and adolescence. **Oral presentation** at the 10th State of the Art Adolescent Medicine Meeting, Athens, Greece (March 17-18, 2017).
154. Vasilakis I, Kazakou P, Kogia C, Karaflou M, Chrousos GP, Charmandari E. (2017) A rare case of ACTH-dependent Cushing syndrome in association with myoclonic dystonia. **Oral presentation** at the 44th Hellenic Endocrine Society Meeting, Thessaloniki, Greece (May 9-12, 2018).
155. Karampatsou S, Genitsaridi S, Papageorgiou I, Charmandari E. (2019) The role of irisin in the pathogenesis of overweight and obesity in childhood and adolescence. **Oral presentation** at the 13<sup>th</sup> Panhellenic Congress of Obesity, Athens, Greece (February 28 – March 2, 2019).
156. Genitsaridi S, Karampatsou S, Papageorgiou I, Mantziou E, Kassari P, Charmandari E. (2019) Hair cortisol concentrations in overweight and obese children and adolescents. **Oral presentation** at the 13<sup>th</sup> Panhellenic Congress of Obesity, Athens, Greece (February 28 – March 2, 2019).
157. Giannios C, Nicolaides N, Farakla I, Papadopoulos G, Genitsaridi S, Karampatsou S, Papageorgiou I, Kolaitis G, Charmandari E. (2019) The effect of vitamin D supplementation in cardiometabolic risk factors in overweight and obese children and adolescents. **Oral presentation** at the 13<sup>th</sup> Panhellenic Congress of Obesity, Athens, Greece (February 28 – March 2, 2019).
158. Tragomalou A, Kassari P, Ioakeimidis I, Filis, K, Theodoropoulou E, Limberopoulos G, Perez Cuevas I, Karavidopoulou G, Diou C, Maramis C, Lekka E, Maglaveras N, Delopulos A, Charmandari E. BigO: Bid Data against Childhood Obesity: Clinical pilot study in Greece. **Oral presentation** at the 12th State-of-the-Art Adolescent Medicine Meeting, Athens, Greece (April 5-6, 2019).
159. Kassari P, Billiris A, Karanikas H, Thireos E, Drakoulis N, Manios Y, Charmandari E. PEDOBESITY: Electronic application for the personalized management of childhood obesity. **Oral presentation** at the 12th State-of-the-Art Adolescent Medicine Meeting, Athens, Greece (April 5-6, 2019).
160. Tragomalou A, Kassari P, Ioakeimidis I, Filis, K, Theodoropoulou E, Limberopoulos G, Perez Cuevas I, Karavidopoulou G, Diou C, Maramis C, Lekka E, Maglaveras N, Delopulos A,

Charmandari E. BigO: Bid Data against Childhood Obesity – A clinical pilot study. **Oral presentation** at the 46th Hellenic Endocrine Society Meeting, Athens, Greece (April 17-20, 2019).

161. Kassari P, Billiris A, Karanikas H, Thireos E, Drakoulis N, Manios Y, Charmandari E. PEDOBESITY: A novel electronic application for the management of overweight and obesity in childhood and adolescence. **Oral presentation** at the 46th Hellenic Endocrine Society Meeting, Athens, Greece (April 17-20, 2019).
162. Tragomalou A, Kassari P, Ioakeimidis I, Filis, K, Theodoropoulou E, Limberopoulos G, Perez Cuevas I, Karavidopoulou G, Diou C, Maramis C, Lekka E, Maglaveras N, Delopulos A, Charmandari E. BigO: Bid Data against Childhood Obesity. **Poster presentation** at the 45th Athens Medical Society Meeting, Athens, Greece (May 15-18, 2019).
163. Kassari P, Billiris A, Karanikas H, Thireos E, Drakoulis N, Manios Y, Charmandari E. PEDOBESITY: A novel electronic application for the personalized management of childhood obesity. **Poster presentation** at the 45th Athens Medical Society Meeting, Athens, Greece (May 15-18, 2019).

## 11. INVITED LECTURES

---

### A/ INVITED LECTURES AT INTERNATIONAL CONFERENCES

1. Charmandari E. (2004) Congenital adrenal hyperplasia and puberty. Invited lecture at 3rd Ferring Pharmaceuticals International Paediatric Endocrinology Symposium, Barcelona, Spain.
2. Charmandari E. (2004) Endocrinologic and psychologic evaluation of 21-hydroxylase deficient carriers and normal subjects: Evidence for physical and psychologic vulnerability to stress. Invited lecture at the 5th International Congress of Neuropsychiatry, Athens, Greece.
3. Charmandari E. (2005) Classic congenital adrenal hyperplasia and the metabolic syndrome. Invited lecture at the 39th Annual Meeting of the European Society for Clinical Investigation, Athens, Greece.
4. Charmandari E. (2006) Generalized glucocorticoid resistance: Clinical phenotype and molecular mechanisms. Invited lecture at the Cortisol Secretion Abnormalities-I Meeting [25 years studying stress mediators: A symposium honouring George P. Chrousos], Bethesda, Maryland, USA.
5. Charmandari E. (2006) Glucocorticoid resistance. Invited lecture at the 12th European Meeting of the International Society for Adolescent Health, Athens, Greece.
6. Charmandari E. (2010) Yearbook of Pediatric Endocrinology - Adrenals. Invited lecture at the 49th European Society for Pediatric Endocrinology Meeting, Prague, Czech Republic. (September 2010).



7. Charmandari E. (2010) Generalized glucocorticoid resistance syndrome. Invited lecture at the Mastercourse in Pediatric Endocrinology, Erasmus MC, Rotterdam, The Netherlands (October 12, 2010).
8. Charmandari E. (2011) Generalized glucocorticoid resistance and hypersensitivity states. Invited lecture at the 45th Annual Scientific Meeting of the European Society for Clinical Investigation, Heraklion, Crete, Greece (April 13-16, 2011).
9. Charmandari E. (2011) Recent advances in steroid receptor research. Invited lecture at the European Society for Pediatric Endocrinology (ESPE) Science School, Berlin, Germany (May 24-26, 2011).
10. Charmandari E. (2011) Precocious Puberty. Invited lecture at the joint Greek-UK Pediatric Meeting, Athens, Greece (May 27-28, 2011).
11. Charmandari E. (2011) Yearbook of Pediatric Endocrinology - Adrenals. Invited lecture at the 50th European Society for Pediatric Endocrinology Meeting, Glasgow, United Kingdom (September 25-28, 2011).
12. Charmandari E. (2012) Primary Generalized Glucocorticoid Resistance and Hypersensitivity States. Invited lecture at the European Society for Pediatric Endocrinology (ESPE) Science School (ESS), Iraklio, Crete, Greece (May 16-20, 2012).
13. Charmandari E. (2012) 2012 Working Party on 'Disorders of Sex Development' (DSD): Evaluation report. Invited lecture at the joint 51st European Society for Pediatric Endocrinology Meeting, Leipzig, Germany (September 20-23, 2012).
14. Charmandari E. (2012) Yearbook of Pediatric Endocrinology - Adrenals. Invited lecture at the 51st European Society for Pediatric Endocrinology Meeting, Leipzig, Germany (September 20-23, 2012).
15. Charmandari E. (2013) Yearbook of Pediatric Endocrinology - Adrenals. Invited lecture at the 9th Joint Meeting of Pediatric Endocrinology, Milan, Italy (September 19-22, 2012).
16. Charmandari E. (2014) Adrenal Insufficiency. Invited lecture at the ESPE Summer School of the 53rd European Society for Pediatric Endocrinology Meeting, Dublin, Ireland (September 14-17, 2014).
17. Charmandari E. (2014) Congenital Adrenal Hyperplasia. Invited (Symposium) lecture at the 53rd European Society for Pediatric Endocrinology Meeting, Dublin, Ireland (September 18-20, 2014).
18. Charmandari E. (2014) Adrenals - Yearbook of Pediatric Endocrinology. Invited lecture at the 53rd European Society for Pediatric Endocrinology Meeting, Dublin, Ireland (September 18-20, 2014).
19. Charmandari E. (2014) Circadian endocrine rhythms: The HPA axis and its actions. Invited lecture at the International Congress on Stress, Chronic Inflammation and Nutrition, Venice, Italy (October 17-18, 2014).

20. Charmandari E. (2015) Rare causes of adrenal failure. Invited lecture at the IPOKRATES Seminar, Athens, Greece (April 20-22, 2015).
21. Charmandari E. (2015) Clinical Research. Invited lecture at the ESPE Science School Meeting, Annecy, France (June 3-6, 2015).
22. Charmandari E. (2015) Adrenals - Yearbook of Pediatric Endocrinology. Invited lecture at the 54th European Society for Pediatric Endocrinology Meeting, Barcelona, Spain (October 1-3, 2015).
23. Charmandari E. (2016) Molecular Mechanisms of Glucocorticoid Action – Syndromes of Generalized Glucocorticoid Resistance and Hypersensitivity. Invited Lecture at the ‘Hot Topics in Pediatric Endocrinology’ Meeting, Stockholm, Sweden (May 12, 2016).
24. Charmandari E. (2016) Adrenals - Yearbook of Pediatric Endocrinology. Invited lecture at the 55th European Society for Pediatric Endocrinology Meeting, Paris, France (September 10-12, 2016).
25. Charmandari E. (2016) National System for the Prevention and Management of Childhood Obesity. Invited lecture at the ‘26<sup>th</sup> European Childhood Obesity Group (ECOG) Congress, Thessaloniki, Greece (October 6-8, 2016).
26. Charmandari E. (2016) Development of a National e-Health System for the Prevention and Management of Childhood Obesity. Invited lecture at the ‘2<sup>nd</sup> Congress of Pharmacogenomics and Personalized Diagnosis and Therapy’ Meeting, Athens, Greece (November 4-6, 2016).
27. Charmandari E. (2017) Managing Cushing’s syndrome in children. Invited lecture at the IPOKRATES Seminar, Athens, Greece (March 6-8, 2017).
28. Charmandari E. (2017) Development of a National System for the Prevention and Management of Childhood Obesity. Invited lecture at the ‘1<sup>st</sup> Hellenic Chinese Congress on Health’, Athens, Greece (May 14-17, 2017).
29. Charmandari E. (2017) Adrenals - Yearbook of Pediatric Endocrinology. Invited lecture at the 56th European Society for Pediatric Endocrinology Meeting, Washington DC, USA (September 14-17, 2017).
30. Charmandari E. (2017) Familial Hyperaldosteronism. Invited lecture at the 56th European Society for Pediatric Endocrinology Meeting, Washington DC, USA (September 14-17, 2017).
31. Charmandari E. (2017) The Adolescent with Difficult Congenital Adrenal Hyperplasia. Invited lecture at the Pfizer Endocrinology First Global Summit 2017, Athens, Greece (October 25-27, 2017).
32. Charmandari E. (2017) Development of a National e-Health System for the Prevention and Management of Childhood Obesity. Invited lecture at the 3rd International Conference in Biomedical and Health Informatics (ICBHI), Thessaloniki, Greece (November 18-21, 2017).
33. Charmandari E. (2018) Advances in the management of Congenital Adrenal Hyperplasia. Invited lecture at the 17th International Postgraduate Course in Endocrine Surgery, Athens, Greece (May 31 – June 2, 2018).

34. Charmandari E. (2018) Adrenals - Yearbook of Pediatric Endocrinology. Invited lecture at the 57th European Society for Pediatric Endocrinology Meeting, Athens, Greece (September 27 – 29, 2018).
35. Charmandari E. (2019) Adrenals - Yearbook of Pediatric Endocrinology. Invited lecture at the 58th European Society for Pediatric Endocrinology Meeting, Vienna, Austria (September 19 – 21, 2019).
36. Charmandari E. (2019) Optimizing treatment in Congenital Adrenal Hyperplasia. Invited lecture at the Annual Meeting of the Spanish Society for Pediatric Endocrinology, Madrid, Spain (October 18, 2019).
37. Charmandari E. (2020) Novel e-health applications for the management of childhood obesity. Invited lecture at the 3rd Congress of Pharmacogenomics and Personalized Diagnosis and Therapy, Athens, Greece (January 10-12, 2019).

## **B/ INVITED LECTURES AT NATIONAL CONFERENCES**

38. Charmandari E. (2007) Classic Congenital Adrenal Hyperplasia. Invited lecture at the Annual Meeting of the Hellenic Society for Pediatric and Adolescent Endocrinology, Athens, Greece.
39. Charmandari E. (2008) Phytoestrogens and Child Health. Invited lecture at the 41st Annual Meeting of the First Department of Pediatrics of the University of Athens, Athens, Greece (April 2008).
40. Charmandari E. (2008) Cushing Syndrome. Invited lecture at the 34th Annual Meeting of the Hellenic Medical Society, Athens, Greece (May 20-24, 2009).
41. Charmandari E. (2008) Glucocorticoids and their Uses. Invited lecture at the Annual Meeting of the Hellenic Society for Pediatric and Adolescent Endocrinology, Athens, Greece.
42. Charmandari E. (2008) Steroid Hormone Receptors. Invited lecture at the Annual Meeting of the Hellenic Endocrine Society, Pelion, Greece (November 21-22, 2009).
43. Charmandari E. (2009) Genetic Forms of Obesity. Invited lecture at the 35th Annual Meeting of the Hellenic Medical Society, Athens, Greece (May 5-9, 2009).
44. Charmandari E. (2009) Macronodular and micronodular Adrenal Hyperplasia. Invited lecture at the Hellenic Endocrine Society Meeting on Adrenal Disorders, Athens, Greece (May 9, 2009).
45. Charmandari E. (2009) Case Presentations in Clinical Pediatric Endocrinology. Invited lecture at the 'Ef'Olis Tis Ylis' Meeting, Athens, Greece (October 10-11, 2009).
46. Charmandari E. (2009) Precocious Puberty. Invited lecture at the Annual Meeting of the Hellenic Endocrine Society, Pelion, Greece (November 21-22, 2009).
47. Charmandari E. (2010) Precocious breast development in girls. Invited lecture at the Annual Meeting of the Hellenic College of Pediatrics, Athens, Greece (March 13-14, 2010).

48. Charmandari E. (2010) Adrenocortical tumors. Invited lecture at the Annual Meeting of the A' Department of Pediatrics, University of Athens Medical School, Athens, Greece (April 2010).
49. Charmandari E. (2010) Exercise and the Adrenals. Invited lecture at the Annual Meeting of Pediatric and Adolescent Endocrinology, University of Athens Medical School, Athens, Greece (September 17-18, 2010).
50. Charmandari E. (2010) Precocious Puberty. Invited lecture at the 'Ef'Olis Tis Ylis' Meeting, Meeting, Athens, Greece (October 8-9, 2010).
51. Charmandari E. (2010) Case Presentations in Clinical Pediatric Endocrinology. Invited lecture at the 'Ef'Olis Tis Ylis' Meeting, Athens, Greece (October 8-9, 2010).
52. Charmandari E. (2011) Genetic causes of obesity. Invited lecture at the 7th Annual Pediatric Meeting 'Earinai Pediatrikai Hmerai', Santorini, Greece (May 5-8, 2011).
53. Charmandari E. (2011) The role of human glucocorticoid receptor in mediating glucocorticoid signal transduction. Invited lecture at the 37th Annual Meeting of the Hellenic Medical Society, Athens, Greece (May 17-20, 2011).
54. Charmandari E. (2011). Glucocorticoids and their Therapeutic Uses. Invited lecture at the Annual Pediatric Respiratory Meeting, Ioannina, Greece (September 8-10, 2011).
55. Charmandari E. (2012). Precocious Puberty. Invited lecture at the 1st Meeting of Developmental and Behavioural Pediatrics and Adolescent Medicine, Athens, Greece (March 3-4, 2012).
56. Charmandari E. (2012). Glucocorticoids and their Therapeutic Uses. Invited lecture at the Annual Meeting of Pediatric Subspecialties, Athens, Greece (March 3-4, 2012).
57. Charmandari E. (2012) Metabolic Syndrome. Invited lecture at the 8th Annual Pediatric Meeting 'Earinai Pediatrikai Hmerai', Santorini, Greece (May 26-29, 2012).
58. Charmandari E. (2012) Classic Congenital Adrenal Hyperplasia. Invited lecture at the Pediatrikes Hmeres – 3rd and 4th Pediatric Clinic, Thessaloniki, Greece (September 29-30, 2012).
59. Charmandari E. (2012) Obesity in Childhood and Adolescence. Invited lecture at the Meeting on Childhood Obesity', Athens, Greece (October 24, 2012).
60. Charmandari E. (2012) Diagnosis and treatment of acute adrenal failure. Invited lecture at the 6th Meeting of the Hellenic College of Pediatrics, Athens, Greece (November 10-11, 2012).
61. Charmandari E. (2013) The Genetics of Obesity and Type 2 Diabetes. Invited lecture at the Department of Obstetrics and Gynaecology, Aretaieion Hospital, Athens, Greece (January 8, 2013).
62. Charmandari E. (2013) Precocious and Delayed Puberty and Congenital Adrenal Hyperplasia. Invited lecture at the Hellenic Endocrine Society Course of Endocrinology Fellows, Athens, Greece (January 14-18, 2013).

63. Charmandari E. (2013) Familial Hyperaldosteronism. Invited lecture at the Hellenic Society for Pediatric Endocrinology, Athens, Greece (February 9, 2013).
64. Charmandari E. (2013) The Greek experience on the use of mekasermine in the treatment of short stature. Invited lecture at the Hellenic Society for Pediatric Endocrinology, Athens, Greece (February 9, 2013).
65. Charmandari E. (2013) Neonatal Screening for Congenital Adrenal Hyperplasia. Invited lecture at the Seminar on Genetics – ‘Aghia Sophia’ Children’s Hospital, Athens, Greece (February 16, 2013).
66. Charmandari E. (2013) Genetics of Obesity. Invited lecture at the 16th Meeting of Intensive Training in Endocrinology and Metabolic Disorders, Athens, Greece (February 22-24, 2013).
67. Charmandari E. (2013) Precocious Puberty. Invited lecture at the Conference of Adolescent Medicine, Athens, Greece (March 2-3, 2013).
68. Charmandari E. (2013) Genetic causes of Obesity in Childhood and Adolescence. Invited lecture at the 8th Meeting of the Hellenic Medical Society of Obesity, Thessaloniki, Greece (March 15-16, 2013).
69. Charmandari E. (2013) ESPA Program on the Prevention and Management of Overweight and Obesity in Childhood and Adolescence. Invited lecture at the 7th Meeting of the Hellenic College of Pediatrics, Athens, Greece (April 5-7, 2013).
70. Charmandari E. (2013) Therapeutic Developments - Adrenals. Invited lecture at the annual ‘Therapeutic Developments’ Meeting, Athens, Greece (April 27, 2013).
71. Charmandari E. (2013) Prevention and management of obesity. Invited lecture at the 46th Annual Treatment Update of the First Department of Pediatrics, University of Athens Medical School, Athens, Greece (May 11-12, 2013).
72. Charmandari E. (2013) Debate: GnRH analogs in the treatment of early puberty – No. Invited lecture at the 1st Combo Endocrinology Course, Monastery ‘Evangelistria’, Viotia, Greece (September 11-14, 2013).
73. Charmandari E. (2013) ESPA Program on the Prevention and Management of Overweight and Obesity in Childhood and Adolescence. Invited lecture at the Meeting on Health and Prevention in Greece, Athens, Greece (October 11-12, 2013).
74. Charmandari E. (2013) Precocious puberty. Invited lecture at the ‘Ef’Olis Tis Ylis’ Meeting, Athens, Greece (October 11-12, 2013).
75. Charmandari E. (2013) Newborns with ambiguous genitalia. Invited lecture at the 17th Panhellenic Congress of Perinatal Medicine, Athens, Greece (November 1-3, 2013).
76. Charmandari E. (2013) Development of a National System for the prevention and management of overweight and obesity in childhood and adolescence in Greece. Invited lecture at the 12<sup>th</sup> Panhellenic Meeting of Nutrition and Dietetics, Athens, Greece (December 5-8, 2013).

77. Charmandari E. (2014) The use of liraglutide in obesity. Invited lecture at the Novonordisk Meeting, Athens, Greece (March 7-8, 2014).
78. Charmandari E. (2014) Glucocorticoid receptor. Invited lecture at the Novonordisk Meeting, Athens, Greece (March 7-8, 2014).
79. Charmandari E. (2014) Newborns with ambiguous genitalia: Diagnosis and management. Invited lecture at the 8th Meeting of the Hellenic College of Pediatrics, Athens, Greece (March 21-22, 2014).
80. Charmandari E. (2014) Congenital Adrenal Hyperplasia. Invited lecture at the 17<sup>th</sup> Postgraduate Course on 'Neuroendocrinology and Adrenals' of the Hellenic Endocrine Society, Athens, Greece (March 29, 2014).
81. Charmandari E. (2014) Childhood obesity. Invited lecture at the 10th Panhellenic Congress of Public Health, Athens, Greece (March 31-April 2, 2014).
82. Charmandari E. (2014) Development of a national system for the prevention and management of obesity in childhood and adolescence. Invited lecture at the 7th State of The Art Adolescent Medicine Course, Athens, Greece (April 4-7, 2014).
83. Charmandari E. (2014) Greek reality in childhood obesity and current preventive strategies. Invited lecture at the European Scientific Meeting on Maternal and Infant Nutrition, Athens, Greece (April 5, 2014).
84. Charmandari E. (2014) Obesity in childhood and adolescence. Invited lecture at the 10th Annual Pediatric Meeting 'Earinai Pediatrikai Hmerai', Nafplio, Greece (April 10-13, 2014).
85. Charmandari E. (2014) Prevention and management of obesity in childhood and adolescence. Invited lecture at the Nestle Pediatric Meeting, Costa Navarino, Greece (May 3, 2014).
86. Charmandari E. (2014) Recent advances in the molecular mechanisms determining tissue sensitivity to glucocorticoids. Invited lecture at the 41st Hellenic Endocrine Society Meeting, Porto Cheli, Greece (May 14-17, 2014).
87. Charmandari E. (2014) Obesity in childhood and adolescence. Invited lecture at the Annual Meeting of the Ministry of Health, Athens, Greece (June 30, 2014).
88. Charmandari E. (2014) Development of a national system for the prevention and management of obesity in childhood and adolescence. Invited lecture at the 1st Panhellenic Congress on Diabetes, Metabolic Syndrome and Obesity, Athens, Greece (October 10-12, 2014).
89. Charmandari E. (2015) The year in Pediatric Endocrinology. Invited lecture at the Annual Endorama Meeting, Patras, Greece (January 30-31, 2015).
90. Charmandari E. (2015) Assessment of the effectiveness of interventions of diet and exercise in overweight and obese children and adolescents. Invited lecture at the 9th Meeting of the Hellenic College of Pediatrics, Athens, Greece (March 13-14, 2015).

91. Charmandari E. (2015) Development of a novel national system for the prevention and management of childhood obesity. Invited lecture at the 8th State of the Art Adolescent Medicine Course, Athens, Greece (March 13-14, 2015).
92. Charmandari E. (2015) Early puberty: Is treatment with GnRH analogues necessary? Invited lecture at the 48th Annual Treatment Update of the First Department of Pediatrics, University of Athens Medical School, Athens, Greece (April 17-19, 2015).
93. Charmandari E. (2015) Prevention and management of childhood obesity in our country: Development of a national system for documentation and therapeutic management. Invited lecture at the Novonordisk Meeting, Athens, Greece (April 24-25, 2015).
94. Charmandari E. (2015) Development of a national system for documentation and therapeutic management of childhood obesity. Invited lecture at the 41st Panhellenic Medical Society Meeting, Athens, Greece (June 10-13, 2015).
95. Charmandari E. (2015) Growth Hormone insufficiency and treatment in survivors of childhood malignancy. Invited lecture at the 41st Panhellenic Medical Society Meeting, Athens, Greece (June 10-13, 2015).
96. Charmandari E. (2015) Development of a national system for the prevention and management of overweight and obesity in childhood and adolescence. Invited lecture at the Meeting for presenting the report on the completion of the ESPA program, Athens, Greece (November 14-15, 2015).
97. Charmandari E. (2015) Prevention and management of childhood obesity: Development of a National System of electronic documentation and therapeutic guidance. Invited lecture at the 13<sup>th</sup> Panhellenic Meeting of Nutrition and Dietetics, Athens, Greece (November 27-29, 2015).
98. Charmandari E. (2015) Development of a National System for the prevention and management of overweight and obesity in childhood and adolescence in Greece. Invited lecture at the eHealth Forum 2015, Athens, Greece (December 3-4, 2015).
99. Charmandari E. (2015) Congenital adrenal hyperplasia: Transition to adulthood. Invited lecture at the Hellenic Pediatric Endocrinology Meeting on Gonadal Disorders, Athens, Greece (December 12, 2015).
100. Charmandari E. (2016) Congenital adrenal hyperplasia. Invited lecture at the Hellenic Pediatric Endocrinology Meeting, Athens, Greece (February 27-28, 2016).
101. Charmandari E. (2016) Molecular mechanisms determining tissue sensitivity to glucocorticoids. Invited lecture at the 19<sup>th</sup> Postgraduate Course on 'Neuroendocrinology and Adrenals' of the Hellenic Endocrine Society, Athens, Greece (March 18-20, 2016).
102. Charmandari E. (2016) Prevention and management of obesity in childhood and adolescence: Development of a National System of electronic documentation and therapeutic guidance. Invited lecture at the 11<sup>th</sup> Panhellenic Meeting of Public Health, Athens, Greece (March 21-23, 2016).
103. Charmandari E. (2016) Prevention and Management of Childhood Obesity: Development of a National System of Electronic Documentation and Guidance for the Prevention and

Management of Childhood Obesity. Invited lecture at the 12th Annual Pediatric Meeting 'Earinai Pediatrikai Hmerai', Corfu, Greece (April 21-33, 2016).

104. Charmandari E. (2016) Prevention and Management of Childhood Obesity. Invited lecture at the 42nd Annual Meeting of Athens Medical Society, Athens, Greece (May 11-14, 2016).
105. Charmandari E. (2016) 'Lose Weight – Gain Life': Development of a National System of Electronic Documentation and Guidance for the Prevention and Management of Childhood Obesity. Invited lecture at the '7<sup>th</sup> Panhellenic Congress of Atherosclerosis', Athens, Greece (December 1-3, 2016).
106. Charmandari E. (2016) Prevention and Management of Obesity in Childhood and Adolescence. Invited lecture at the '4<sup>th</sup> Congress of Medical Responsibility and Bioethics', Athens, Greece (December 9-10, 2016).
107. Charmandari E. (2017) Molecular mechanisms of glucocorticoid action – Syndromes of generalized glucocorticoid resistance and hypersensitivity. Invited lecture at the '1<sup>st</sup> Panhellenic Congress of the Institute of Biology and Medicine of Stress', Athens, Greece (January 20-22, 2017).
108. Charmandari E. (2017) Monogenic disorders of childhood obesity. Invited lecture at the '5<sup>th</sup> Panhellenic Congress of Adolescent Health and Medicine', Athens, Greece (February 3-4, 2017).
109. Charmandari E. (2017) National Registry for the Prevention and Management of Overweight and Obesity in Childhood and Adolescence. Invited lecture at the DYO Forum Meeting, Athens, Greece (February 11-12, 2017).
110. Charmandari E. (2017) eHealth: Development of an Electronic National System for the Prevention and Management of Childhood Obesity. Invited lecture at the 2nd Panhellenic Congress of Pediatric and Adolescent Endocrinology, Athens, Greece (February 18-19, 2017).
111. Charmandari E. (2017) Development of a National System of Electronic Documentation and Guidance for the Prevention and Management of Childhood Obesity. Invited lecture at the '26<sup>th</sup> Medical Symposium of 251 General Airforce Hospital', Athens, Greece (February 20, 2017).
112. Charmandari E. (2017) Non-traditional cardiovascular risk factors of metabolic syndrome in children and adolescents. Invited lecture at the '10th Annual Meeting of the Hellenic Medical Society for Obesity, Athens, Greece (March 3-4, 2017).
113. Charmandari E. (2017) Obesity in childhood and adolescence: Recent clinical and research data from the out-patient clinic on the prevention and management of increased body-weight. Invited lecture at the '4th Meeting of Applied Dietetics and Nutrition', Athens, Greece (March 17-18, 2017).
114. Charmandari E. (2017) Classic Congenital Adrenal Hyperplasia: New therapeutic modalities. Invited lecture at the 13th Annual Pediatric Meeting 'Earinai Pediatrikai Hmerai', Tinos, Greece (April 7-9, 2017).
115. Charmandari E. (2017) Epigenetics and Adrenals. Invited lecture at the 44th Hellenic Endocrine Society Meeting, Athens, Greece (April 26-29, 2017).



116. Charmandari E. (2017) Introduction to the Methodology of Research. Invited lecture at the Seminar on the 'Introduction on the Methodology of Research and Statistical Analysis', Athens, Greece (June 10-11, 2017).
117. Charmandari E. (2017) Physiology of menstruation. Invited lecture at the 5th Panhellenic Meeting of Pediatric and Adolescent Endocrinology, Athens, Greece (October 6-8, 2017).
118. Charmandari E. (2017) Lose Weight – Gain Life: Development of a National System for the Prevention and Management of Childhood Obesity. Invited lecture at the '29th Pagkritio Pediatric Congress, Heraklio, Greece (October 21-22, 2017).
119. Charmandari E. (2017) Classic Congenital Adrenal Hyperplasia: Novel therapeutic approaches. Invited lecture at the 2nd Panhellenic Symposium of the Hellenic Society of Obesity in Childhood and Adolescence, Athens, Greece (November 10-11, 2017).
120. Charmandari E. (2017) Classic Congenital Adrenal Hyperplasia in adolescence. Invited lecture at the 18th Meeting on the Female Endocrinology, Athens, Greece (December 16, 2017).
121. Charmandari E. (2018) Precocious Puberty. Invited lecture at the 14th Annual Pediatric Meeting 'Earinai Pediatrikai Hmerai', Spetes, Greece (March 30 April 1, 2018).
122. Charmandari E. (2018) Gender dysphoria. Invited lecture at the 51st Annual Meeting of the First Department of Pediatrics, University of Athens Medical School, Athens, Greece (April 14-15, 2018).
123. Charmandari E. (2018) Gender identity – Endocrinologic approach. Invited lecture at the 11th State of the Art Adolescent Medicine Course, Athens, Greece (April 20-21, 2018).
124. Charmandari E. (2018) Recent advances in Pediatrics. Invited lecture at the 44th Panhellenic Meeting of Athens Medical Society, Athens, Greece (May 9-12, 2018).
125. Charmandari E. (2018) Classic Congenital Adrenal Hyperplasia. Invited lecture at the Symposium of Clinical Genetics and Genomics, Athens, Greece (June 1-2, 2018).
126. Charmandari E. (2018) Gender dysphoria. Invited lecture at the 7th Annual Meeting of Developmental and Behavioural Pediatrics, Athens, Greece (October 6-7, 2018).
127. Charmandari E. (2019) Ambiguous genitalia. Invited lecture at the 15th Annual Pediatric Meeting 'Earinai Pediatrikai Hmerai', Spetes, Greece (April 18-21, 2019).
128. Charmandari E. (2019) The use of novel e-health applications for the management of overweight and obesity in childhood and adolescence. Invited lecture at the Annual Meeting of the Hellenic Society for Pediatric Endocrinology, Athens, Greece (May 10-12, 2019).
129. Charmandari E. (2019) Introduction to the Methodology of Research. Invited lecture at the Seminar on the 'Introduction on the Methodology of Research and Statistical Analysis', Athens, Greece (June 7-8, 2019).

130. Charmandari E. (2019) Concensus guidelines for the management of Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency. Invited lecture at the 4th Symposium of the Hellenic Society of Childhood and Adolescent Obesity, Athens, Greece (October 11-12, 2019).

---

## 12. RESEARCH FUNDING

---

**Funding attracted as a main PI: 1,688,000.00 Euros**

**Funding attracted as co-PI: 789,000.00 Euros.**

**Total Funding: 2,477,000.00**

1. Charmandari E (PI), Chrousos GP (Co-PI). Functional characterization of the human glucocorticoid receptor mutations, F737L and D401H, causing generalized glucocorticoid resistance – *General Secretariat of Research and Development*, Athens, Greece – **78,000** Euros; 2007 – 2009.
  2. Chrousos GP (PI), Charmandari E (Co-PI). Gas5 and Obesity – *Ministry of Health*, Athens, Greece – **10,000** Euros; 2009 - 2010.
  3. Chrousos GP (PI), Charmandari E (Co-PI). Molecular mechanisms of membrane glucocorticoid receptor action – *Hrakteitos, Ministry of Education*, Athens, Greece – **45,000** Euros; 2010 - 2013.
  4. Charmandari E (PI). Molecular mechanisms of nongenomic glucocorticoid actions – *Hellenic Endocrine Society*, Athens, Greece – **5,000** Euros; 2011 - 2012.
  5. Chrousos GP (PI), Charmandari E (Co-PI). Molecular mechanisms and clinical implications of glucocorticoid receptor action – *Thalis, Ministry of Education*, Athens, Greece – **600,000** Euros; 2011 – 2015.
  6. Charmandari E (PI). Prevention and management of overweight and obesity in childhood and adolescence – *ESPA, Ministry of Health*, Athens, Greece – **1,000,000** Euros; 2012 – 2014.
  7. Charmandari E (PI). Molecular mechanisms determining tissue sensitivity to glucocorticoids – *Hellenic Endocrine Society*, Athens, Greece – **5,000** Euros; 2013 - 2014.
  8. Delopoulos A (PI), Charmandari E (Co-PI). Big data against childhood Obesity – Horizon 2020 Framework Programme H2020-SC1-2016-2017 (H2020-SC1-2016-CNECT) – **134,000** Euros; 2017 – 2020.
  9. 9. Charmandari E (PI), Datamed (Private company). Artificial Intelligence Algorithms for Personalized Management of Obesity in Childhood and Adolescence. Operational Programme Competitiveness, Entrepreneurship and Innovation 2014-2020 (EPAnEK) – **600,000** Euros; 2018-2021.
-

## 13. TEACHING

---

### A. UNDERGRADUATE EDUCATION

- Regular Teaching of the Undergraduate Students in Molecular Endocrinology and Cellular Biology at the Biomedical Research Foundation of the Academy of Athens (2007 – Present)
- Regular Teaching of Medical Students in Pediatric and Adolescent Endocrinology according to the Program defined by the University of Athens and the First Department of Pediatrics, ‘Aghia Sophia’ Children’s Hospital (2009 – Present)
- Examination of Medical Students in General Pediatrics (2011 – Present)
- Teaching of Medical Students in the Elective Course ‘Clinical Endocrinology’ – Scientific Supervisor: Professor Evanthia Diamanti-Kandarakis (2012 – 2016)
- Teaching of Medical Students in the Elective Course ‘Pediatric Psychiatry’ – Scientific Supervisor: Associate Professor Gerasimos Kolaitis (2013 – Present)

### B. POSTGRADUATE EDUCATION

- Regular Teaching of the Senior House Officers (Residents) in General Pediatrics, as well as participation in their preparation for the specialty examinations (2009 – Present)
  - Regular Teaching of the Fellows in Pediatric Endocrinology (2011 – Present)
  - Regular Teaching at the Annual Intensive Course in Endocrinology (2012 – Present)
  - Regular Teaching of the MSc and PhD Students in Molecular Endocrinology and Cellular Biology at the National Institute of Child Health and Human Development, National Institutes of Health (2000-20004)
  - Regular Teaching of the Postgraduate Students in Molecular Endocrinology and Cellular Biology at the Biomedical Research Foundation of the Academy of Athens (2007 – Present)
  - Teaching of the MSc Students of the Postgraduate Course ‘Research in Reproductive Endocrinology’ – Scientific Supervisor: Associate Professor George Mastorakos (2008 – Present)
  - Teaching of the MSc Students of the Postgraduate Course ‘Molecular and Applied Physiology’ – Scientific Supervisor: Professor Michael Koutsilieris (2012 – Present)
  - Teaching of the MSc Students of the Postgraduate Course ‘Clinical Pediatrics and Nursing: Research’ – Scientific Supervisor: Professor Evangelia Charmandari and Professor Vassiliki Gemou (2015 – 2018)
  - Teaching of the MSc Students of the Postgraduate Course ‘General Pediatrics and Pediatric Subspecialties: Clinical Practice and Research’ – Scientific Supervisor: Professor Evangelia Charmandari (2018 – Present)
- 
- Participation and organization of the Postgraduate Program of the European Society for Clinical Investigation entitled ‘Steroid Receptors’ (Heraklio, Crete, 2011)
  - Participation and organization of the Postgraduate Program of the European Society for Pediatric Endocrinology (ESPE) entitled ‘The New Inroads to Child Health (NICHe) Conference’ (Heraklio, Crete, 2012)
  - Participation and organization of the Postgraduate Program of the European Society for Pediatric Endocrinology (ESPE) entitled ‘ESPE Science School’ (Heraklio, Crete, 2012)
  - Participation and organization of the Postgraduate Program entitled ‘Optimal nutrition in infancy and childhood’ (Costa Navarino, May, 2014)

- Participation and organization of the Annual Meetings of Hellenic College of Pediatrics and Hellenic Society of Pediatric and Adolescent Endocrinology (2011 – Present)

### **C. SUPERVISION OF MSc STUDENTS, PhD STUDENTS AND POSTDOCTORAL SCIENTISTS**

- Main Scientific Supervisor of 2 Undergraduate Students, 10 MSc Students, 3 PhD Students and 3 Postdoctoral Scientists, who have completed their research projects.
- Main scientific supervisor of 8 MSc Students, 5 PhD Students and 1 Postdoctoral Scientist, whose research studies are still ongoing.

### **14. EUROPEAN SOCIETY FOR PEDIATRIC ENDOCRINOLOGY (ESPE) ACTIVITIES AND AWARDS**

---

- Member of the European Society for Paediatric Endocrinology (1998 – Present)
- Member of the ESPE Clinical Practice Committee (CPC) (2011 – 2016)
- Chair of the ESPE Clinical Practice Committee (CPC) (2016 – Present)
- Chair of the Intersociety Clinical Guidelines Committee (2016 – Present)
- Member of the ESPE Council (2016 – Present)
- Member (ex-Officio) of the ESPE Programme Organising Committee (2016 – Present)
- Member (ex-Officio) of the ESPE Communication Committee (2016 – Present)
- Member of the ESPE Science School (ESS) Committee (2013 – 2016)
- Member of the Scientific and Organizing Committee of the ESS Conferences (2012, 2015)
- Associate Editor, Yearbook of Pediatric Endocrinology (2010 – Present)
- 2007 ‘Henning Andersen’ Prize for Basic Research
- 2015 ‘ESPE Research Unit’ Collaborative Project Grant

### **15. ORGANIZATION OF CONFERENCES**

---

1. Kino T, Charmandari E, Chrousos GP. Basic and clinical implications of glucocorticoid action – Focus on Development. July 17-18, 2003. National Institutes of Health, Bethesda, Maryland, USA.
2. Charmandari E. Workshop on Steroid Receptors - European Society for Clinical Investigation Meeting, Heraklio, Crete, Greece; April 14-16, 2011.
3. Theodoridou M, Charmandari E, Chrousos GP. Joint UK - Greek Pediatric Meeting, Athens, Greece; May 28-29, 2011.
4. Chrousos GP, Charmandari E, Carel JA, Achermann JC, Soder O. The European Society for Pediatric Endocrinology (ESPE) Science School (ESS), Heraklio, Crete, Greece; May 16-17, 2012.
5. Chrousos GP, Charmandari E, Carel JA, Achermann JC, Soder O. The New Inroads to Child Health (NICHe) Conference, Heraklio, Crete, Greece; May 18-20, 2012.

6. Charmandari E, Chrousos GP, Abrahamian A, Vazaiou A. Conference on Childhood Obesity, Athens, Greece, October 24, 2012.
7. Charmandari E. Development of a National System for the Prevention and Management of Overweight and Obesity in Childhood and Adolescence. Athens, Greece; June 5, 2013.
8. Charmandari E. Prevention and management of overweight and obesity in childhood and adolescence. Athens, Greece; October 24, 2013.
9. Charmandari E. An Update on the Development of a National System for the Prevention and Management of Overweight and Obesity in Childhood and Adolescence. Athens, Greece; November 20-21, 2015.
10. Organization of the Annual Meetings of the Hellenic College of Pediatrics (2011 – Present).
11. Organization of the Annual Meetings of the Hellenic Society of Pediatric Endocrinology (2011 – Present).

## **16. MEMBERSHIP IN EDITORIAL BOARDS AND SOCIETY BOARDS**

---

1. Associate Editor, *Pediatrica* (2008 – 2011)
2. Associate Editor, *Clinicae Paediatricae Universitatis Atheniensis* (2009 – Present)
3. Associate Editor, *Yearbook of Pediatric Endocrinology* (2010 – Present)
4. Chair, Committee for Approval of Growth Hormone Treatment (2011 – 2017)
5. Secretary General, Hellenic College of Pediatrics (2014 – Present)
6. Secretary General, Hellenic Society for Pediatric and Adolescent Endocrinology (2015 – 2018)
7. Member, Hellenic Society for Pediatric and Adolescent Endocrinology (2018 – Present)
8. ESPE Council (2016 – Present)

## **17. MEMBERSHIP IN SOCIETIES AND COMMITTEES**

---

1. The Endocrine Society (2000 – Present)
2. European Society for Pediatric Endocrinology (ESPE) (1998 – Present)
3. ESPE Clinical Practice Committee (2011 – Present)
4. ECOS International Scientific Steering Committee (2011 – Present)
5. ESPE Science School Committee (2013 – Present)
6. Hellenic College of Pediatrics (2011 – Present)
7. Hellenic Society for Pediatric and Adolescent Endocrinology (2008 – Present)
8. Hellenic Endocrine Society (2008 – Present)
9. Hellenic Medical Society for Obesity (2008 – Present)
10. Society for Endocrinology (1998 – 2012)
11. British Society for Pediatric Endocrinology and Diabetes (1998 – 2012)
12. Knowledge Network Forum on the Advances of Growth Hormone Research (2010-2012)
13. European Society for Clinical Investigation (2012 – 2014)
14. Member, Clinical Practice Committee of ESPE (2010 – 2016)
15. Chair, Clinical Practice Committee of ESPE (2016 – Present)

16. Chair of the Intersociety Clinical Guidelines Committee (2016 – Present)
17. Member (ex-Officio) of the ESPE Programme Organising Committee (2016 – Present)
18. Member (ex-Officio) of the ESPE Communication Committee (2016 – Present)
19. Member of the ESPE Science School (ESS) Committee (2013 – 2016)